```
* * * * * * * * * * * * * * * * STN  Columbus  *
* * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:03:42 ON 26 APR
1998

=> index bioscience

COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
0.15       0.15

INDEX 'AGRICOLA, AIDSLINE, ANABSTR, AQUASCI,
BIOBUSINESS, BIOSIS, BIOTECHABS,
       BIOTECHDS, CABA, CANCERLIT, CAPLUS,
CEABA, CEN, CIN, CJACS, CONFSCI,
       CROPB, CROPU, DDFB, DDFU, DGENE,
DISSABS, DRUGB, DRUGLAUNCH, DRUGNL,
       DRUGU, EMBAL, EMBASE, FSTA, GENBANK,
...' ENTERED AT 19:03:54 ON 26 APR 1998

49 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term
postings or to view
search error messages that display as 0* with
SET DETAIL OFF.

=> s igf? or (insulin?(3a) (growth factor?))

        954   FILE AGRICOLA
         90   FILE AIDSLINE
         36   FILE ANABSTR
        127   FILE AQUASCI
       1014   FILE BIOBUSINESS
      22432   FILE BIOSIS
        517   FILE BIOTECHABS
        517   FILE BIOTECHDS
  8 FILES SEARCHED...
       2548   FILE CABA
       6500   FILE CANCERLIT
 10 FILES SEARCHED...
      15486   FILE CAPLUS
        163   FILE CEABA
         15   FILE CEN
        130   FILE CIN
        253   FILE CJACS
        845   FILE CONFSCI
          5   FILE CROPU
        139   FILE DDFB
       1818   FILE DDFU
       1289   FILE DGENE
 21 FILES SEARCHED...
        750   FILE DISSABS
        139   FILE DRUGB
         73   FILE DRUGNL
       2281   FILE DRUGU
        266   FILE EMBAL
      14107   FILE EMBASE
         50   FILE FSTA
      13936   FILE GENBANK
          6   FILE HEALSAFE
 31 FILES SEARCHED...
        813   FILE IFIPAT
       1416   FILE JICST-EPLUS
         19   FILE KOSMET
       4394   FILE LIFESCI
      16989   FILE MEDLINE
 36 FILES SEARCHED...
         23   FILE NIOSHTIC
         84   FILE NTIS
         28   FILE OCEAN
         38   FILE PHAR
          3   FILE PHIC
        297   FILE PHIN
        749   FILE PROMT
      16541   FILE SCISEARCH
 44 FILES SEARCHED...
       2354   FILE TOXLINE
      10021   FILE TOXLIT
       3150   FILE USPATFULL
       2223   FILE WPIDS
       2223   FILE WPINDEX

  47 FILES HAVE ONE OR MORE ANSWERS,   49
FILES SEARCHED IN STNINDEX

L1   QUE IGF? OR (INSULIN?(3A) (GROWTH
FACTOR?))

=> s l1 and stroke?

          5   FILE BIOBUSINESS
         24   FILE BIOSIS
          2   FILE BIOTECHABS
          2   FILE BIOTECHDS
          4   FILE CANCERLIT
 10 FILES SEARCHED...
         24   FILE CAPLUS
          2   FILE CEABA
          3   FILE CEN
          1   FILE CIN
         11   FILE CJACS
          8   FILE DDFU
         66   FILE DGENE
          2   FILE DISSABS
          6   FILE DRUGNL
         17   FILE DRUGU
          1   FILE EMBAL
         19   FILE EMBASE
 28 FILES SEARCHED...
          3   FILE IFIPAT
          2   FILE LIFESCI
         22   FILE MEDLINE
 38 FILES SEARCHED...
          1   FILE PHAR
         22   FILE PHIN
         33   FILE PROMT
         15   FILE SCISEARCH
          5   FILE TOXLINE
         12   FILE TOXLIT
        116   FILE USPATFULL
          9   FILE WPIDS
          9   FILE WPINDEX

  29 FILES HAVE ONE OR MORE ANSWERS,   49
FILES SEARCHED IN STNINDEX

L2   QUE L1 AND STROKE?


=> s l1 and (cns? or brain? or
(central?(3a)(neur? or nerv?)))

         15   FILE AGRICOLA
          1   FILE ANABSTR
         11   FILE AQUASCI
         14   FILE BIOBUSINESS
       1006   FILE BIOSIS
  6 FILES SEARCHED...
         13   FILE BIOTECHABS
         13   FILE BIOTECHDS
         67   FILE CABA
        294   FILE CANCERLIT
 10 FILES SEARCHED...
        933   FILE CAPLUS
          8   FILE CEABA
```

```
          2   FILE CEN
          7   FILE CIN
         45   FILE CJACS
         11   FILE CONFSCI
          3   FILE DDFB
         28   FILE DDFU
         23   FILE DGENE
         70   FILE DISSABS
  22 FILES SEARCHED...
          3   FILE DRUGB
         41   FILE DRUGNL
         51   FILE DRUGU
         13   FILE EMBAL
       1022   FILE EMBASE
  28 FILES SEARCHED...
          1   FILE FSTA
         89   FILE GENBANK
         23   FILE IFIPAT
         80   FILE JICST-EPLUS
  33 FILES SEARCHED...
        294   FILE LIFESCI
        894   FILE MEDLINE
  36 FILES SEARCHED...
          3   FILE OCEAN
          2   FILE PHAR
          1   FILE PHIC
         41   FILE PHIN
        112   FILE PROMT
        893   FILE SCISEARCH
  44 FILES SEARCHED...
        114   FILE TOXLINE
        519   FILE TOXLIT
  46 FILES SEARCHED...
        552   FILE USPATFULL
         31   FILE WPIDS
         31   FILE WPINDEX

  41 FILES HAVE ONE OR MORE ANSWERS,   49
FILES SEARCHED IN STNINDEX

L3   QUE L1 AND (CNS? OR BRAIN? OR
(CENTRAL?(3A)(NEUR? OR NERV?)))

=> s l3 and (stroke? or trauma?)

          2   FILE BIOBUSINESS
         19   FILE BIOSIS
   6 FILES SEARCHED...
          1   FILE BIOTECHABS
          1   FILE BIOTECHDS
          2   FILE CANCERLIT
  10 FILES SEARCHED...
         37   FILE CAPLUS
          2   FILE CEABA
          1   FILE CEN
          1   FILE CIN
          6   FILE CJACS
          1   FILE DGENE
          3   FILE DISSABS
  22 FILES SEARCHED...
          7   FILE DRUGNL
          1   FILE DRUGU
          2   FILE EMBAL
         20   FILE EMBASE
  28 FILES SEARCHED...
          6   FILE IFIPAT
          5   FILE LIFESCI
  35 FILES SEARCHED...
         16   FILE MEDLINE
  36 FILES SEARCHED...
          1   FILE PHAR
         13   FILE PHIN
         25   FILE PROMT
         21   FILE SCISEARCH
  44 FILES SEARCHED...
          2   FILE TOXLINE
          6   FILE TOXLIT
  46 FILES SEARCHED...
        150   FILE USPATFULL
         12   FILE WPIDS
         12   FILE WPINDEX

  28 FILES HAVE ONE OR MORE ANSWERS,   49
FILES SEARCHED IN STNINDEX

L4   QUE L3 AND (STROKE? OR TRAUMA?)

=> file uspatfull

COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
37.80      37.95

FILE 'USPATFULL' ENTERED AT 19:54:06 ON 26
APR 1998
CA INDEXING COPYRIGHT (C) 1998 AMERICAN
CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE:
21 Apr 1998 (19980421/PD)
FILE LAST UPDATED: 22 Apr 1998 (19980422/ED)
HIGHEST PATENT NUMBER: US5742935
CA INDEXING IS CURRENT THROUGH 22 Apr 1998
(19980422/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH:
21 Apr 1998 (19980421/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:
JAN 1998
USPTO MANUAL OF CLASSIFICATIONS THESAURUS
ISSUE DATE: Feb 1998

=> s l4

       2502 IGF?
       9480 INSULIN?
     133294 GROWTH
     409226 FACTOR?
       8291 GROWTH FACTOR?
              (GROWTH(W)FACTOR?)
       1301 INSULIN?(3A) (GROWTH FACTOR?)
       4487 CNS?
      21405 BRAIN?
     632703 CENTRAL?
      25591 NEUR?
      23797 NERV?
      10873 CENTRAL?(3A)(NEUR? OR NERV?)
     112338 STROKE?
      15512 TRAUMA?
L5      150 L3 AND (STROKE? OR TRAUMA?)

=> d 140-150


L5   ANSWER 140 OF 150  USPATFULL
AN     92:84854  USPATFULL
TI     Method for potentiation of a
therapeutic agent
IN     Garcia y Bellon, Donato P., Ponciano
Arriaga #28 PB, Col. Centro,
       Cuauhtemoc, Mexico  06030
       Garcia, Jr., Donato P., 4558 Blvd.
Agua Cliente Col. Aviacion,
       Tijuana, Mexico  22420
       Ayre, Steven G., 483 First St.,
Antioch, IL, United States  60002
PI     US 5155096  921013
AI     US 90-615621  901119 (7)
```

RLI Continuation-in-part of Ser. No. US 87-77833, filed on 27 Jul 1987, now patented, Pat. No. US 4971951
DT Utility
LN.CNT 978
INCL INCLM: 514/003.000
INCLS: 514/004.000; 514/825.000; 514/885.000; 514/886.000; 514/893.000; 514/966.000; 514/967.000
NCL NCLM: 514/003.000
NCLS: 514/004.000; 514/825.000; 514/885.000; 514/886.000; 514/893.000; 514/966.000; 514/967.000
IC [5]
ICM: A61K037-26
EXF 514/3; 514/4; 424/825; 424/885; 424/886; 424/893; 424/966; 424/967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 141 OF 150 USPATFULL
AN 92:84797 USPATFULL
TI Use of thrombospondin to promote wound healing
IN Eyal, Jacob, Baltimore, MD, United States
Tuszynski, George, Mays Landing, NJ, United States
PA W. R. Grace & Co.-Conn., New York, NY, United States (U.S. corporation)
Medical College of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5155038 921013
AI US 90-483500 900222 (7)
DT Utility
LN.CNT 353
INCL INCLM: 435/240.200
INCLS: 514/008.000; 435/070.210; 424/077.000
NCL NCLM: 514/008.000
NCLS: 424/077.000; 435/070.210
IC [5]
ICM: C12P021-02
ICS: C12N005-00; A01N025-24; A61K037-10
EXF 514/8; 435/70.21; 435/240.2; 424/77
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 142 OF 150 USPATFULL
AN 92:82339 USPATFULL
TI System for diagnosis and treatment of wounds
IN Eriksson, Elof, Boston, MA, United States
PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5152757 921006
AI US 91-707248 910522 (7)
RLI Continuation of Ser. No. US 89-451957, filed on 14 Dec 1989, now abandoned
DT Utility
LN.CNT 1211
INCL INCLM: 604/305.000
NCL NCLM: 604/305.000
IC [5]
ICM: A61F013-00
EXF 604/304-308; 424/DIG.13; 623/15; 128/369; 128/370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 143 OF 150 USPATFULL
AN 92:40820 USPATFULL
TI Amphiregulin: a bifunctional growth modulating glycoprotein
IN Shoyab, Mohammed, Seattle, WA, United States
McDonald, Vicki L., Kent, WA, United States
Bradley, James G., Woodinville, WA, United States
Plowman, Gregory D., Seattle, WA, United States
PA Oncogen, Seattle, WA, United States (U.S. corporation)
PI US 5115096 920519
AI US 89-297816 890117 (7)
RLI Continuation-in-part of Ser. No. US 88-181884, filed on 15 Apr 1988, now abandoned which is a continuation-in-part of Ser. No. US 88-148327, filed on 25 Jan 1988, now abandoned
DT Utility
LN.CNT 2689
INCL INCLM: 530/322.000
INCLS: 530/324.000
NCL NCLM: 530/322.000
NCLS: 530/324.000
IC [5]
ICM: C07K009-00
EXF 530/322
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 144 OF 150 USPATFULL
AN 92:35989 USPATFULL
TI Processes for producing collagen matrixes and methods of using same
IN Chu, George H., Sunnyvale, CA, United States
Ogawa, Yasushi, Pacifica, CA, United States
McPherson, John M., Framingham, MA, United States
Ksander, George, Redwood City, CA, United States
Pratt, Bruce, Union City, CA, United States
Hendricks, Diana, Brea, CA, United States
McMullin, Hugh, San Bruno, CA, United States
PA Collagen Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 5110604 920505
AI US 90-630299 901219 (7)
RLI Division of Ser. No. US 88-213726, filed on 30 Jun 1988, now patented, Pat. No. US 5024841
DT Utility
LN.CNT 711
INCL INCLM: 424/484.000
INCLS: 424/422.000; 424/085.200; 424/085.400; 514/801.000; 530/356.000; 530/399.000; 604/890.100
NCL NCLM: 424/484.000
NCLS: 128/DIG.008; 424/085.200; 424/085.400; 424/422.000; 514/801.000; 530/356.000; 530/399.000; 604/890.100; 623/011.000
IC [5]

ICM: A61K009-14
ICS: A61K037-66; A61K037-12; A61K037-24
EXF 424/422-426; 424/444; 424/484; 424/85.2; 424/85.4; 623/16; 514/801; 514/56; 530/356; 530/399; 604/890.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 145 OF 150 USPATFULL
AN 92:17110 USPATFULL
TI Treating disorders by application of **insulin**-like **growth factor**
IN Lewis, Michael E., Landenberg, PA, United States
Kauer, James C., Kennett Square, PA, United States
Smith, Kevin R., Downington, PA, United States
Callison, Kathleen V., Merchantville, NJ, United States
Baldino, Jr., Frank, Landenberg, PA, United States
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5093317 920303
AI US 89-361595 890605 (7)
DT Utility
LN.CNT 858
INCL INCLM: 514/012.000
INCLS: 514/003.000; 514/004.000; 514/885.000; 514/903.000; 514/021.000; 424/556.000; 424/570.000
NCL NCLM: 514/012.000
NCLS: 424/556.000; 424/570.000; 514/003.000; 514/004.000; 514/021.000; 514/885.000; 514/903.000
IC [5]
ICM: A61K037-36
ICS: A61K037-26
EXF 424/98; 424/556; 424/570; 514/3; 514/4; 514/12; 514/21; 514/885; 514/903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 146 OF 150 USPATFULL
AN 91:84437 USPATFULL
TI Method for preventing tissue damage after an ischemic episode
IN Sheffield, Warren D., Lebanon, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 5057494 911015
AI US 88-227579 880803 (7)
DT Utility
LN.CNT 487
INCL INCLM: 514/012.000
INCLS: 514/021.000
NCL NCLM: 514/012.000
NCLS: 514/021.000
IC [5]
ICM: A61K037-02
ICS: A61K037-36
EXF 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 147 OF 150 USPATFULL
AN 91:48454 USPATFULL
TI Collagen wound healing matrices and process for their production
IN Chu, George H., Sunnyvale, CA, United States
Ogawa, Yasushi, Pacifica, CA, United States
McPherson, John M., Hopkinton, MA, United States
Ksander, George, Redwood City, CA, United States
Pratt, Bruce, Union City, CA, United States
Hendricks, Diana, Brea, CA, United States
McMullin, Hugh, San Bruno, CA, United States
PA Collagen Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 5024841 910618
AI US 88-213726 880630 (7)
DT Utility
LN.CNT 759
INCL INCLM: 424/422.000
INCLS: 424/484.000; 424/085.200; 424/085.400; 424/426.000; 530/356.000; 530/399.000; 514/056.000; 514/801.000; 604/890.100
NCL NCLM: 424/422.000
NCLS: 128/DIG.008; 424/085.200; 424/085.400; 424/426.000; 424/484.000; 514/056.000; 514/801.000; 530/356.000; 530/399.000; 604/890.100; 623/011.000
IC [5]
ICM: A61F013-00
ICS: A61K009-14; A61K037-12; A61K031-725
EXF 424/422-426; 424/444; 424/484; 424/85.2; 424/85.4; 623/16; 514/801; 514/56; 530/356; 530/399; 604/890.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 148 OF 150 USPATFULL
AN 88:441 USPATFULL
TI Apparatus and method for adjusting heart/pacer rate relative to cardiac pCO.sub.2 to obtain a required cardiac output
IN Koning, Gerrit, Vries, Netherlands
Schroeppel, Edward A., Miamar, FL, United States
PA Telectronics N.V., Curacao, Netherlands Antilles (non-U.S. corporation)
PI US 4716887 880105
AI US 85-722575 850411 (6)
DT Utility
LN.CNT 946
INCL INCLM: 128/419.000PG
INCLS: 128/635.000
NCL NCLM: 607/024.000
NCLS: 600/353.000; 607/016.000; 607/022.000
IC [4]
ICM: A61N001-36
EXF 128/635; 128/2; 128/419PG

L5 ANSWER 149 OF 150 USPATFULL
AN 87:82990 USPATFULL
TI Novel phosphotyrosyl protein phosphatase
IN Liang, Theming, Miami, FL, United States

Slater, Eve E., Short Hills, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4710469 871201
AI US 86-858622 860502 (6)
DT Utility
LN.CNT 638
INCL INCLM: 435/194.000
INCLS: 530/352.000
NCL NCLM: 435/194.000
NCLS: 530/352.000
IC [4]
ICM: C12N009-12
EXF 435/194; 530/352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 150 OF 150 USPATFULL
AN 87:74975 USPATFULL
TI DNA sequences encoding erythropoietin
IN Lin, Fu-Kuen, Thousand Oaks, CA, United States
PA Kiren-Amgen, Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 4703008 871027
AI US 84-675298 841130 (6)
RLI Continuation-in-part of Ser. No. US 83-561024, filed on 13 Dec 1983, now abandoned And a continuation-in-part of Ser. No. US 84-582185, filed on 21 Feb 1984, now abandoned And a continuation-in-part of Ser. No. US 84-655841, filed on 28 Sep 1984
DT Utility
LN.CNT 2313
INCL INCLM: 435/240.200
INCLS: 435/172.300; 435/253.000; 435/006.000; 435/317.000; 435/320.000; 536/027.000; 935/009.000; 935/010.000; 935/013.000; 935/079.000; 935/080.000
NCL NCLM: 435/360.000
NCLS: 435/006.000; 435/172.300; 435/252.300; 435/252.330; 435/320.100; 435/365.100; 536/023.510; 536/023.720; 536/024.100; 536/024.300; 536/024.310; 536/025.320; 930/090.000; 935/009.000; 935/010.000; 935/013.000; 935/079.000; 935/080.000
IC [4]
ICM: C12N005-00
ICS: C12N015-00; C12N001-20; C12N001-00; C12Q001-68; C07H015-12
EXF 435/68; 435/317; 435/172.3; 435/253; 435/240; 935/6; 935/10; 935/11; 935/27; 935/69; 935/73; 935/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 150 kwic

L5 ANSWER 150 OF 150 USPATFULL
DETD . . . plates containing 50 micrograms/ml Ampicillin. GeneScreen filters (New England Nuclear Catalog No. NEF-972) were pre-wet on a BHI-CAM plate (Bacto **brain** heart infusion 37 g/L, Casamino acids 2 g/L and agar 15 g/L, containing 500 micrograms/ml Chloramphenicol) and were used to. . .
DETD . . . Included within the class of humans treatable with products of the invention are patients generally reguiring blood transfusions and including **trauma** victims, surgical patients, renal disease patients including dialysis patients, and patients with a variety of blood composition affecting disorders, such. . .
DETD . . . use in compositions of the invention include compounds independently noted for erythropoietic stimulatory effects, such as testosterones, progenitor cell stimulators, **insulin** -like **growth factor**, prostaglandins, serotonin, cyclic AMP, prolactin and triiodothyzonine, as well as agents generally employed in treatment of aplastic anemia, such as. . .

=> s l3 and (stroke?)

2502 IGF?
9480 INSULIN?
133294 GROWTH
409226 FACTOR?
8291 GROWTH FACTOR? (GROWTH(W)FACTOR?)
1301 INSULIN?(3A) (GROWTH FACTOR?)
4487 CNS?
21405 BRAIN?
632703 CENTRAL?
25591 NEUR?
23797 NERV?
10873 CENTRAL?(3A)(NEUR? OR NERV?)
112338 STROKE?
L6 73 L3 AND (STROKE?)

=> d 60-73

L6 ANSWER 60 OF 73 USPATFULL
AN 96:20903 USPATFULL
TI Composition useful for in vivo delivery of biologics and methods employing same
IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champaign, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champaign, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)
PI US 5498421 960312
AI US 94-200235 940222 (8)
RLI Continuation-in-part of Ser. No. US 93-23698, filed on 22 Feb

1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 93-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
LN.CNT 3321
INCL INCLM: 424/450.000
INCLS: 424/451.000; 424/455.000; 424/009.300; 424/009.340; 424/009.370; 424/009.400; 424/009.500
NCL NCLM: 424/450.000
NCLS: 424/009.300; 424/009.340; 424/009.370; 424/009.400; 424/009.500; 424/451.000; 424/455.000
IC [6]
ICM: A61K037-22
ICS: A61K009-127
EXF 424/451; 424/45; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 61 OF 73 USPATFULL
AN 96:9366 USPATFULL
TI Glucose-regulated promoter of yeast acetyl-CoA hydrolase
IN Smith, John A., Scotch Plains, NJ, United States
Lee, Fang-Jen S., North Bethesda, MD, United States
Lin, Lee-Wen, North Bethesda, MD, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5487990 960130
AI US 92-921796 920730 (7)
RLI Continuation-in-part of Ser. No. US 90-480452, filed on 15 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 88-213943, filed on 1 Jul 1988, now abandoned And a continuation-in-part of Ser. No. US 89-297003, filed on 13 Jan 1989, now abandoned
DT Utility
LN.CNT 2244
INCL INCLM: 435/172.300
INCLS: 435/254.200; 435/254.210; 435/254.220; 435/254.230; 435/320.100; 536/024.100; 935/037.000; 935/069.000; 530/371.000
NCL NCLM: 435/172.300
NCLS: 435/254.200; 435/254.210; 435/254.220; 435/254.230; 435/320.100; 530/371.000; 536/024.100; 935/037.000; 935/069.000
IC [6]
ICM: C12N001-19
ICS: C12N015-81; C12N015-11
EXF 536/24.1; 530/371; 435/320.1; 435/254.2; 435/254.21; 435/254.22; 435/254.23; 435/172.3; 935/37; 935/69
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 62 OF 73 USPATFULL
AN 95:110557 USPATFULL
TI Fused Pyrrolocarbazoles
IN Hudkins, Robert L., Chester Springs, PA, United States
Knight, Jr., Ernest, Wilmington, DE, United States
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5475110 951212
AI US 94-323755 941014 (8)
DT Utility
LN.CNT 2781
INCL INCLM: 546/256.000
INCLS: 546/271.000; 548/417.000
NCL NCLM: 546/256.000
NCLS: 536/017.400; 546/022.000; 546/276.700; 548/416.000; 548/417.000; 548/418.000; 548/469.000
IC [6]
ICM: C07D487-06
EXF 548/417; 546/256; 546/271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 63 OF 73 USPATFULL
AN 95:64902 USPATFULL
TI Neuropeptide antagonists
IN Rozengurt, Enrique, London, England
Woll, Penella, London, England
PA Imperial Cancer Research Technology, Ltd., London, England (non-U.S. corporation)
PI US 5434132 950718
AI US 93-147896 931102 (8)
RLI Continuation of Ser. No. US 92-994443, filed on 23 Dec 1992 which is a continuation of Ser. No. US 90-573158, filed on 19 Oct 1990, now abandoned
PRAI GB 88-664 880321
DT Utility
LN.CNT 1192
INCL INCLM: 514/002.000
INCLS: 530/329.000; 530/314.000; 530/315.000
NCL NCLM: 514/002.000
NCLS: 530/314.000; 530/315.000; 530/329.000
IC [6]
ICM: A61K038-08
ICS: A61K038-11; A61K038-16; C07K011-00
EXF 424/198.1; 530/326; 530/327; 530/328; 530/329; 514/2; 514/314; 514/315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 73 USPATFULL
AN 95:64843 USPATFULL
TI Fibrinolytic and anti-thrombotic cleavable dimers
IN Dawson, Keith, Marlow, United Kingdom
Hunter, Michael G., Aylesbury, United Kingdom
Czaplewski, Lloyd G., Didcot, United Kingdom
PA British Bio-Technology Limited, Oxford, England (non-U.S. corporation)
PI US 5434073 950718
WO 9109125 910627
AI US 92-854596 920603 (7)
WO 90-GB1911 901207
920603 PCT 371 date
920603 PCT 102(e) date
PRAI GB 89-27722 891207
DT Utility
LN.CNT 2191
INCL INCLM: 435/216.000

INCLS: 530/350.000; 530/402.000; 435/069.700; 424/094.640
NCL NCLM: 435/216.000
NCLS: 424/094.640; 435/069.700; 530/350.000; 530/402.000
IC [6]
ICM: C12N009-70
ICS: C07K013-00
EXF 435/69.7; 435/216; 530/402; 530/350; 424/94.64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 73 USPATFULL
AN 94:80075 USPATFULL
TI Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
IN Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5346991 940913
AI US 91-714819 910613 (7)
DT Utility
LN.CNT 2407
INCL INCLM: 530/350.000
INCLS: 530/381.000; 530/829.000; 435/172.300
NCL NCLM: 530/350.000
NCLS: 435/172.300; 530/381.000; 530/829.000
IC [5]
ICM: C07K013-00
ICS: C12N015-12; A61K037-02
EXF 435/172.1; 435/172.3; 530/350; 530/381; 530/829; 514/822
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 73 USPATFULL
AN 94:62555 USPATFULL
TI Purified active somatostatin receptor
IN Eppler, Cecil M., Langhorne, PA, United States
Zysk, John R., Frenchtown, NJ, United States
Corbett, Martin J., Mt. Holly, NJ, United States
Shieh, Hong-Ming, Langhorne, PA, United States
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5331094 940719
AI US 92-963246 921019 (7)
RLI Continuation of Ser. No. US 91-677009, filed on 28 Mar 1991, now abandoned
DT Utility
LN.CNT 1080
INCL INCLM: 530/395.000
INCLS: 530/350.000
NCL NCLM: 530/395.000
NCLS: 530/350.000
IC [5]
ICM: C07K015-06
ICS: C07K015-14
EXF 530/350; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 67 OF 73 USPATFULL
AN 93:54857 USPATFULL
TI Receptors method for purification of G protein-linked
IN Eppler, Cecil M., Langhorne, PA, United States
Shieh, Hong-Ming, Langhorne, PA, United States
Zysk, John R., Frenchtown, NJ, United States
Corbett, Martin J., Pemberton, NJ, United States
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5225543 930706
AI US 91-677003 910328 (7)
DT Utility
LN.CNT 1336
INCL INCLM: 530/413.000
INCLS: 530/395.000; 530/412.000; 530/415.000
NCL NCLM: 530/413.000
NCLS: 530/395.000; 530/412.000; 530/415.000
IC [5]
ICM: C07K003-20
ICS: C07K003-12; C07K003-18; C07K003-28
EXF 530/307; 530/311; 530/350; 530/367; 530/387; 530/412; 530/413; 530/415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 73 USPATFULL
AN 93:6941 USPATFULL
TI Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
IN Friden, Phillip M., Bedford, MA, United States
PA Alkermes, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5182107 930126
AI US 92-846830 920306 (7)
RLI Continuation-in-part of Ser. No. US 89-404089, filed on 7 Sep 1989
DT Utility
LN.CNT 1327
INCL INCLM: 424/085.910
INCLS: 424/085.800; 424/094.100; 530/387.300; 530/391.100; 530/391.700; 530/391.900; 530/399.000; 530/388.220; 514/021.000
NCL NCLM: 424/179.100
NCLS: 424/094.100; 424/143.100; 424/178.100; 514/021.000; 530/387.300; 530/388.220; 530/391.100; 530/391.700; 530/391.900; 530/399.000
IC [5]
ICM: A61K039-44
ICS: A61K037-36; C07K017-02; C07K015-28
EXF 530/391.1; 530/391.7; 530/391.9; 530/387.3; 530/399; 530/388.22; 424/85.91; 424/85.8; 424/94.1; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 69 OF 73 USPATFULL
AN 92:84797 USPATFULL
TI Use of thrombospondin to promote wound healing
IN Eyal, Jacob, Baltimore, MD, United States

Tuszynski, George, Mays Landing, NJ, United States
PA W. R. Grace & Co.-Conn., New York, NY, United States (U.S. corporation)
Medical College of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5155038 921013
AI US 90-483500 900222 (7)
DT Utility
LN.CNT 353
INCL INCLM: 435/240.200
INCLS: 514/008.000; 435/070.210; 424/077.000
NCL NCLM: 514/008.000
NCLS: 424/077.000; 435/070.210
IC [5]
ICM: C12P021-02
ICS: C12N005-00; A01N025-24; A61K037-10
EXF 514/8; 435/70.21; 435/240.2; 424/77
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 70 OF 73 USPATFULL
AN 92:17110 USPATFULL
TI Treating disorders by application of **insulin**-like
growth factor
IN Lewis, Michael E., Landenberg, PA, United States
Kauer, James C., Kennett Square, PA, United States
Smith, Kevin R., Downington, PA, United States
Callison, Kathleen V., Merchantville, NJ, United States
Baldino, Jr., Frank, Landenberg, PA, United States
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5093317 920303
AI US 89-361595 890605 (7)
DT Utility
LN.CNT 858
INCL INCLM: 514/012.000
INCLS: 514/003.000; 514/004.000; 514/885.000; 514/903.000;
514/021.000; 424/556.000; 424/570.000
NCL NCLM: 514/012.000
NCLS: 424/556.000; 424/570.000; 514/003.000; 514/004.000;
514/021.000; 514/885.000; 514/903.000
IC [5]
ICM: A61K037-36
ICS: A61K037-26
EXF 424/98; 424/556; 424/570; 514/3; 514/4; 514/12; 514/21; 514/885; 514/903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 71 OF 73 USPATFULL
AN 91:84437 USPATFULL
TI Method for preventing tissue damage after an ischemic episode
IN Sheffield, Warren D., Lebanon, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 5057494 911015
AI US 88-227579 880803 (7)
DT Utility
LN.CNT 487
INCL INCLM: 514/012.000
INCLS: 514/021.000
NCL NCLM: 514/012.000
NCLS: 514/021.000
IC [5]
ICM: A61K037-02
ICS: A61K037-36
EXF 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 73 USPATFULL
AN 88:441 USPATFULL
TI Apparatus and method for adjusting heart/pacer rate relative to
cardiac pCO.sub.2 to obtain a required cardiac output
IN Koning, Gerrit, Vries, Netherlands
Schroeppel, Edward A., Miamar, FL, United States
PA Telectronics N.V., Curacao, Netherlands Antilles (non-U.S. corporation)
PI US 4716887 880105
AI US 85-722575 850411 (6)
DT Utility
LN.CNT 946
INCL INCLM: 128/419.000PG
INCLS: 128/635.000
NCL NCLM: 607/024.000
NCLS: 600/353.000; 607/016.000; 607/022.000
IC [4]
ICM: A61N001-36
EXF 128/635; 128/2; 128/419PG

L6 ANSWER 73 OF 73 USPATFULL
AN 87:82990 USPATFULL
TI Novel phosphotyrosyl protein phosphatase
IN Liang, Theming, Miami, FL, United States
Slater, Eve E., Short Hills, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4710469 871201
AI US 86-858622 860502 (6)
DT Utility
LN.CNT 638
INCL INCLM: 435/194.000
INCLS: 530/352.000
NCL NCLM: 435/194.000
NCLS: 530/352.000
IC [4]
ICM: C12N009-12
EXF 435/194; 530/352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 71 kwic

L6 ANSWER 71 OF 73 USPATFULL
SUMM . . . macroscopic area of necrosis. Tissues that are likely to
be affected by a reduction of blood supply and oxygen are
central nervous system (**CNS**),
myocardial, renal, spleen, intestinal and lung tissues.
SUMM . . . an area of the heart muscle usually as a result of
occlusion of a coronary artery; and cerebral ischemia or

stroke, which is a neurological affliction resulting from the sudden reduction in cerebral blood supply. The term " **stroke**" (sometimes called apoplexy) is a lay term which refers to the sudden diminution or loss of consciousness, sensation and voluntary motion caused by rupture or obstruction of an artery of the **brain**. **Stroke** is usually more specifically described by the nature of the underlying disturbance, e.g. thrombosis, hemorrhage or embolism.

SUMM Cerebral ischemia may be distiguished from hypoxia, which is the interference with the oxygen supply to the **brain** despite a relatively normal cerebral blood flow and normal perfusion pressure. Cerebral hypoxia occurs for a variety of reasons, including. . .

SUMM . . . event that is sufficiently severe and in an appropriate location to leave persistent disability but is short of a calamatous **stroke**, is defined as a partial nonprogressing **stroke** (PNS). The ultimate in severity of ischemia produces a more major degree of permanent neurologic disability, sometimes referred to as a completed **stroke**.

In those cases where the ischemia has been prolonged, neuronal cell death occurs. The **brain** softens and the margins between the gray and white matter become indistinct. Under the microscope the neurons (if still present). . .

SUMM Present therapies for treating or preventing ischemic events, such as cerebral **stroke**, include risk factor management, anti-spasmodic drugs, anti-thrombotic drugs and surgery. These therapies have disadvantages and are not always successful.

Therefore,. . . methods for the direct protection of neurons and/or glia cells (aka neuroglia cells, which are non-neuronal cellular elements of the **central** and peripheral **nervous** systems) following cerebral ischemia and the present invention provides such methods.

SUMM . . . FGF may be beneficial in the treatment of Alzheimer's disease as well as treatment of other neurodegenerative disorders of the **CNS** involving loss of non-cholinerigic neurons such as **stroke**, epilepsy or ischemia. In spite of the known neurotrophic nature of FGF, prior to the present invention, no one has. . .

SUMM . . . therewith. The growth factor may be used alone or in combination with other growth factors, such as FGF, NGF, plateletderived **growth factor**, **insulin** -like **growth factor** or transforming growth factor (alpha or beta). The EGF may be administered to the patient separately or in combination with. . .

SUMM . . . generally in the range of 2-5 minutes. In one embodiment, the present methods may be used to treat neuronal or **CNS** tissue, such as is present in the **brain** and spinal cord of the **CNS**. It is envisioned that the present methods may also be useful for treating other types of tissues such as myocardial. . .

SUMM In those instances where **CNS** tissue is to be treated, direct injection into the **CNS** is preferred, such as by intracerebral or intraventricular injection or by injection into the cerebro- spinal fluid or spinal cord. For injection into the **CNS**, catheters, needles and syringes may be used. Infusion of the EGF or FGF via a catheter into the **brain** is an alternative method of administration.

SUMM . . . merely for illustrative Purposes. For instance, the present methods may be used to minimize damage and increase survival time in **stroke** patients. They may be used as a preventative treatment of TIA patients to reduce subsequent serious **stroke** and increase patient and cell survival.

They may be used to reduce risk for spinal ischemia and in cases of. . . time available during surgery when aortic clamping is used. The present invention may be used to treat indications affecting the **brain**, such as **stroke**, cardiac arrest and post-resuscitation damage to the **brain** (e.g., from drowning or subarachnoidal hemorrhage). Indications affecting the heart that may be treated are, for example: post myocardial infarct. . .

DETD The present example is based on a surgical procedure that has been developed to study the effects of cerebral or **brain** ischemia in the unanesthetized gerbil. The methodology is based upon the surgical isolation and instrumentation of both common carotid arteries.. . . occlusion are readily demonstrated by the occurrence of altered spontaneous locomotor activity at various times postischemia. Behavioral changes consequent to

stroke are useful and pertinent as a means of evaluation
in this model of nonlethal transient ischemia Emotional lability,
depression, agitation and motor and cognitive deficits are common
after **stroke**. The psychomotor depression noted
immediately after transient ischemia in this gerbil model mimics
the clinical situation in humans. Spontaneous motor. . .
DETD . . . ligatures. Spontaneous motor activity was then
periodically monitered over seven days followed by animal
sacrifice and blinded histological evaluation of **brain**
sections. EGF (0.1 and 1.0 mg/kg) and FGF (0.1, 1.0 and 10.0
mg/kg) were given intraperitoneally in saline at one. . .

=> d ab

L6 ANSWER 1 OF 73 USPATFULL
AB Disclosed are nucleic acids encoding novel neurotrophic factors,
designated NNT-1. Also disclosed are amino acid sequences for
NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and
other related aspects.

=> d 50-59

L6 ANSWER 50 OF 73 USPATFULL
AN 97:1574 USPATFULL
TI Fused pyrrolocarbazoles
IN Hudkins, Robert L., Chester Springs, PA, United States
Knight, Jr., Ernest, Wilmington, DE, United States
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5591855 970107
AI US 95-427160 950424 (8)
RLI Continuation-in-part of Ser. No. US 94-323755, filed on 14 Oct
1994, now patented, Pat. No. US 5475110
DT Utility
LN.CNT 3293
INCL INCLM: 546/256.000
INCLS: 546/022.000; 546/276.700; 548/417.000; 548/110.000;
548/103.000
NCL NCLM: 546/256.000
NCLS: 546/276.700; 548/103.000; 548/110.000; 548/417.000
IC [6]
ICM: C07D487-06
EXF 548/417; 546/256; 546/271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 73 USPATFULL
AN 96:120775 USPATFULL
TI DNA encoding tissue factor mutants useful for the treatment of
myocardial infarction and coagulopathic disorders
IN Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5589363 961231
AI US 94-246978 940520 (8)
RLI Division of Ser. No. US 91-714819, filed on 13 Jun 1991, now
patented, Pat. No. US 5346991
DT Utility
LN.CNT 2528
INCL INCLM: 435/069.600
INCLS: 530/381.000; 536/023.500; 536/023.400; 435/172.300;
435/240.200; 435/252.300
NCL NCLM: 435/069.600
NCLS: 435/172.300; 435/252.300; 435/325.000; 435/348.000;
435/358.000; 435/369.000; 435/419.000; 530/381.000;
536/023.400; 536/023.500
IC [6]
ICM: C07K014-745
ICS: C12N001-13; C12N015-12; C12N015-63
EXF 435/69.6; 435/172.3; 435/252.3; 435/240.1; 435/320.1; 435/240.2;
530/350; 530/381; 536/23.5; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 73 USPATFULL
AN 96:111367 USPATFULL
TI Generation of neural precursor cell lines
IN Bernard, Ora, North Balwyn, Australia
Bartlett, Perry F., North Carlton, Australia
PA Amrad Corporation Limited, Australia (non-U.S. corporation)
PI US 5580777 961203
AI US 94-330114 941027 (8)
RLI Continuation of Ser. No. US 92-935357, filed on 27 Aug 1992, now
abandoned which is a continuation of Ser. No. US 90-536423, filed
on 28 Jun 1990, now abandoned
PRAI AU 87-5131 871029
DT Utility
LN.CNT 924
INCL INCLM: 435/240.200
INCLS: 435/172.300; 435/320.100
NCL NCLM: 435/172.300
NCLS: 435/320.100; 435/325.000; 435/354.000; 435/368.000;
435/373.000; 435/377.000
IC [6]
ICM: C12N015-00
ICS: C12N005-00
EXF 435/172.3; 435/320.1; 435/240.2

L6 ANSWER 53 OF 73 USPATFULL
AN 96:111313 USPATFULL
TI Methods of determining chemicals that modulate transcriptionally
expression of genes associated with cardiovascular disease
IN Foulkes, J. Gordon, Huntington Station, NY, United States
Liechtfried, Franz E., Vienna, Austria
Pieler, Christian, Vienna, Austria
Stephenson, John R., Santa Cruz, CA, United States

Case, Casey C., Lynbrook, NY, United States
PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)
PI US 5580722 961203
AI US 92-832905 920207 (7)
RLI Continuation-in-part of Ser. No. US 90-555196, filed on 18 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 89-382712, filed on 18 Jul 1989, now abandoned
DT Utility
LN.CNT 4011
INCL INCLM: 435/006.000
INCLS: 435/091.100; 435/091.200; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200; 935/077.000; 935/078.000
IC [6]
ICM: C12P019-34
ICS: C12Q001-68
EXF 435/6; 435/91; 435/91.1; 435/91.2; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 73 USPATFULL
AN 96:101657 USPATFULL
TI Cardiac hypertrophy factor
IN Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)
PI US 5571893 961105
AI US 94-286304 940805 (8)
RLI Continuation of Ser. No. US 94-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DT Utility
LN.CNT 4056
INCL INCLM: 530/350.000
INCLS: 530/399.000; 530/351.000; 930/140.000
NCL NCLM: 530/350.000
NCLS: 530/351.000; 530/399.000; 930/140.000
IC [6]
ICM: C07K014-52
ICS: A61K038-19
EXF 530/350; 530/399; 530/351; 514/12; 930/140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 55 OF 73 USPATFULL
AN 96:101443 USPATFULL
TI Detection and amplification of candiotrophin-1(cardiac hypertrophy factor)
IN Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)
PI US 5571675 961105
AI US 95-444083 950517 (8)
RLI Division of Ser. No. US 94-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 94-233609, filed on 25 Apr 1994
DT Utility
LN.CNT 4298
INCL INCLM: 435/006.000
INCLS: 435/091.200; 435/091.210; 536/024.300; 536/024.310; 536/024.320; 536/024.330
NCL NCLM: 435/006.000
NCLS: 435/091.200; 435/091.210; 536/024.300; 536/024.310; 536/024.320; 536/024.330
IC [6]
ICM: C12Q001-68
ICS: C12P019-34; C07H021-04
EXF 435/6; 435/91.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 73 USPATFULL
AN 96:94687 USPATFULL
TI Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon
IN McCully, Kilmer S., 15 Wildwood St., Winchester, MA, United States 01890
PI US 5565558 961015
AI US 94-366638 941230 (8)
DT Utility
LN.CNT 778
INCL INCLM: 536/026.400
INCLS: 536/026.410; 549/003.000; 549/029.000; 549/060.000; 556/138.000
NCL NCLM: 536/026.400
NCLS: 536/026.410; 549/003.000; 549/029.000; 549/060.000; 556/138.000
IC [6]
ICM: C07H019-167
ICS: A61K031-365; C07D411-00; C07D333-20
EXF 530/351; 424/85.4; 424/85.5; 424/85.6; 424/85.7; 536/26.4; 536/26.41; 549/3; 549/29; 549/60; 556/138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 57 OF 73 USPATFULL
AN 96:82674 USPATFULL
TI Methods for neuroprotection
IN Simpkins, James W., Gainesville, FL, United States
Singh, Meharvan, Gainesville, FL, United States

Bishop, Jean, Jacksonville, FL, United States
PA University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 5554601 960910
AI US 94-318042 941004 (8)
RLI Continuation-in-part of Ser. No. US 93-149175, filed on 5 Nov 1993, now abandoned
DT Utility
LN.CNT 1532
INCL INCLM: 514/182.000
INCLS: 514/181.000
NCL NCLM: 514/182.000
NCLS: 514/181.000
IC [6]
ICM: A61K031-56
EXF 514/171; 514/170; 514/169; 514/179; 514/181; 514/182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 73 USPATFULL
AN 96:60798 USPATFULL
TI Cardiac hypertrophy factor and uses therefor
IN Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennice, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5534615 960709
AI US 94-233609 940425 (8)
DT Utility
LN.CNT 3897
INCL INCLM: 530/350.000
INCLS: 530/380.000; 424/569.000; 424/570.000
NCL NCLM: 530/350.000
NCLS: 424/569.000; 424/570.000; 530/380.000
IC [6]
ICM: C07K001-00
ICS: A61K035-14; A61K035-30
EXF 530/350; 530/380; 424/569; 424/570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 59 OF 73 USPATFULL
AN 96:53046 USPATFULL
TI Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
IN Friden, Phillip M., Bedford, MA, United States
PA Alkermes, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5527527 960618
AI US 93-4986 930115 (8)
RLI Continuation-in-part of Ser. No. US 92-846830, filed on 6 Mar 1992, now patented, Pat. No. US 5182107 which is a continuation-in-part of Ser. No. US 89-404089, filed on 7 Sep 1989, now patented, Pat. No. US 5154924
DT Utility
LN.CNT 1464
INCL INCLM: 424/178.100
INCLS: 530/391.100; 530/391.700; 530/399.000
NCL NCLM: 424/178.100
NCLS: 530/391.100; 530/391.700; 530/399.000
IC [6]
ICM: A61K039-44
ICS: C07K014-48; C07K016-46; C07K017-02
EXF 530/391.1; 530/391.7; 530/399; 530/394; 530/359; 530/303; 530/315; 530/388; 530/389; 514/3; 514/8; 514/12; 514/21; 514/7; 424/85.91; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 40-49

L6 ANSWER 40 OF 73 USPATFULL
AN 97:51729 USPATFULL
TI Methods for the preparation of nucleic acids for in vivo delivery
IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champaign, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champaign, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)
PI US 5639473 970617
AI US 95-483295 950607 (8)
RLI Division of Ser. No. US 94-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 93-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 93-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
LN.CNT 3232
INCL INCLM: 424/450.000
INCLS: 424/482.000; 424/488.000; 424/486.000; 424/009.510
NCL NCLM: 424/450.000
NCLS: 424/009.510; 424/482.000; 424/486.000; 424/488.000
IC [6]
ICM: A61K009-127
EXF 424/450; 424/482; 424/488; 424/486; 424/9.51
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 73 USPATFULL
AN 97:47123 USPATFULL
TI Methods for the preparation of blood substitutes for in vivo delivery

IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champaign, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champaign, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)
PI US 5635207 970603
AI US 95-480621 950607 (8)
RLI Division of Ser. No. US 94-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 93-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 93-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
LN.CNT 3309
INCL INCLM: 424/450.000
INCLS: 424/489.000; 424/001.170
NCL NCLM: 424/450.000
NCLS: 424/001.170; 424/489.000
IC [6]
ICM: A61K009-127
EXF 424/1.17; 424/450; 424/489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 73 USPATFULL
AN 97:42862 USPATFULL
TI Method for producing in vivo delivery of therapeutic agents via liposomes
IN Dzau, Victor J., 12101 Dawn La., Los Altos Hills, CA, United States 94022
Kaneda, Yasufumi, Molecular & Cellular Institute, Osaka University, 1-3, Yamada-oka, Suita-City, Osaka 565, Japan
PI US 5631237 970520
AI US 94-241372 940510 (8)
RLI Continuation-in-part of Ser. No. US 92-995022, filed on 22 Dec 1992, now abandoned
DT Utility
LN.CNT 2435
INCL INCLM: 514/044.000
INCLS: 424/450.000; 424/417.000; 428/402.200; 264/004.100; 264/004.300; 264/004.600
NCL NCLM: 514/044.000
NCLS: 264/004.100; 264/004.300; 264/004.600; 424/417.000; 424/450.000; 428/402.200
IC [6]
ICM: A61K048-00
ICS: A61K009-127
EXF 514/44; 514/2; 424/93.1; 424/450; 424/283.1; 424/1.21; 424/1.25; 435/320.1; 435/69.1; 435/5; 435/193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 73 USPATFULL
AN 97:38416 USPATFULL
TI Hybridomas producing antibodies to cardiac hypertrophy factor
IN Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PA Genentech, Inc., United States (U.S. corporation)
The Regents of the University of California, United States (U.S. corporation)
PI US 5627073 970506
AI US 95-443129 950517 (8)
RLI Division of Ser. No. US 94-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 94-233609, filed on 25 Apr 1994, now abandoned
DT Utility
LN.CNT 4258
INCL INCLM: 435/331.000
INCLS: 435/070.210; 435/172.100; 435/069.600; 435/252.330; 435/332.000; 435/336.000; 530/387.900; 530/388.230; 530/387.300; 530/391.300; 424/139.100; 424/145.100
NCL NCLM: 435/331.000
NCLS: 424/139.100; 424/145.100; 435/069.600; 435/070.210; 435/172.100; 435/252.330; 435/332.000; 435/336.000; 530/387.300; 530/387.900; 530/388.230; 530/391.300
IC [6]
ICM: C12N005-18
ICS: C12N005-22
EXF 424/139.1; 424/145.1; 424/152.1; 424/158.1; 424/172.1; 424/178.1; 424/136.1; 435/69.6; 435/70.21; 435/172.2; 435/172.1; 435/172.3; 435/240.27; 435/252.33; 530/387.3; 530/387.9; 530/388.15; 530/388.23; 530/388.24; 530/391.3; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 73 USPATFULL
AN 97:36158 USPATFULL
TI Method for administering neurologic agents to the **brain**
IN Frey, II, William H., North Oaks, MN, United States
PA Ramsey Foundation, St. Paul, MN, United States (U.S. corporation)
PI US 5624898 970429
AI US 94-361877 941222 (8)
RLI Continuation of Ser. No. US 93-161337, filed on 2 Dec 1993, now abandoned which is a continuation of Ser. No. US 92-879556, filed on 4 May 1992, now abandoned which is a continuation of Ser. No. US 89-446308, filed on 5 Dec 1989, now abandoned
DT Utility
LN.CNT 620
INCL INCLM: 514/012.000

INCLS: 530/300.000; 530/324.000; 530/402.000; 424/400.000
NCL NCLM: 514/012.000
NCLS: 424/400.000; 530/300.000; 530/324.000; 530/402.000
IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K001-00
EXF 514/12; 530/324; 530/402; 530/810; 530/300; 424/400; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 73 USPATFULL
AN 97:36067 USPATFULL
TI Antibodies to cardiac hypertrophy factor and uses thereof
IN Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5624806 970429
AI US 95-442745 950517 (8)
RLI Division of Ser. No. US 94-286304, filed on 5 Aug 1994 which is a continuation of Ser. No. US 94-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DT Utility
LN.CNT 4254
INCL INCLM: 435/007.100
INCLS: 435/240.270; 530/387.900; 530/388.850; 530/387.300; 530/391.300
NCL NCLM: 435/007.100
NCLS: 435/331.000; 435/344.100; 530/387.300; 530/387.900; 530/388.850; 530/391.300
IC [6]
ICM: G01N033-53
ICS: C12N005-12; C07K016-22
EXF 530/387.1; 530/389.1; 530/389.2; 530/388.24; 530/387.24; 530/387.9; 530/388.85; 530/391.3; 530/888.1; 530/388.15; 530/387.3; 424/130.1; 424/145.1; 424/139.1; 424/7.24; 424/156.1; 424/141.1; 424/142.1; 424/133.1; 424/178.1; 424/136.1; 435/240.27; 435/70.21; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 73 USPATFULL
AN 97:20504 USPATFULL
TI Treatment of congestive heart failure
IN Clark, Ross G., Pacifica, CA, United States
Jin, Hongkui, San Bruno, CA, United States
Paoni, Nicholas F., Belmont, CA, United States
Yang, Renhui, San Bruno, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5610134 970311
AI US 94-333909 941103 (8)
RLI Continuation of Ser. No. US 94-284859, filed on 2 Aug 1994 which is a continuation of Ser. No. US 94-227923, filed on 15 Apr 1994, now abandoned
DT Utility
LN.CNT 1257
INCL INCLM: 514/002.000
INCLS: 514/423.000
NCL NCLM: 514/002.000
NCLS: 514/423.000
IC [6]
ICM: A61K038-00
ICS: A61K031-40
EXF 514/2; 514/423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 73 USPATFULL
AN 97:14767 USPATFULL
TI Recombinant human basic fibroblast growth factor
IN Fiddes, John C., Palo Alto, CA, United States
Abraham, Judith A., Sunnyvale, CA, United States
PA Scios Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5604293 970218
AI US 94-221462 940401 (8)
RLI Continuation of Ser. No. US 92-860688, filed on 30 Mar 1992, now abandoned which is a continuation of Ser. No. US 87-50706, filed on 15 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 86-869382, filed on 30 May 1986, now abandoned And Ser. No. US 85-809163, filed on 16 Dec 1985, now patented, Pat. No. US 5439818 And Ser. No. US 85-775521, filed on 12 Sep 1985, now abandoned
DT Utility
LN.CNT 1715
INCL INCLM: 530/399.000
INCLS: 930/010.000
NCL NCLM: 530/399.000
NCLS: 930/010.000
IC [6]
ICM: C07K014-50
EXF 530/399; 530/350; 514/12; 930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 73 USPATFULL
AN 97:5885 USPATFULL
TI Family of map2 protein kinases
IN Boulton, Teri G., Irving, TX, United States
Cobb, Melanie H., Dallas, TX, United States
Yancopoulos, George D., Elmhurst, NY, United States
Nye, Steven, New York, NY, United States
Panayotatos, Nikos, Orangeburg, NY, United States
PA Board of Regents, Univ. of Texas, Dallas, TX, United States (U.S. corporation)

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
(U.S. corporation)
PI US 5595904 970121
AI US 94-176620 940103 (8)
RLI Division of Ser. No. US 91-701544, filed on 16 May 1991, now
abandoned Continuation-in-part of Ser. No. US 90-532004, filed on
1 Jun 1990, now abandoned
DT Utility
LN.CNT 2571
INCL INCLM: 435/240.200
INCLS: 435/243.000; 435/252.800; 435/254.200; 435/320.100;
536/023.500
NCL NCLM: 435/325.000
NCLS: 435/243.000; 435/252.800; 435/254.200; 435/320.100;
435/348.000; 435/353.000; 536/023.500
IC [6]
ICM: C12N005-00
EXF 800/2; 800/205; 800/DIG.1; 435/254.2; 435/172.3; 435/240.1;
435/240.2; 435/320.1; 435/243; 435/252.8; 536/23.1; 536/23.5;
536/24.31
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 73 USPATFULL
AN 97:3856 USPATFULL
TI Fused pyrrolocarbazoles
IN Hudkins, Robert L., Chester Springs, PA, United States
Knight, Jr., Ernest, Wilmington, DE, United States
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5594009 970114
AI US 95-452335 950526 (8)
RLI Continuation-in-part of Ser. No. US 95-427160, filed on 24 Apr
1995 which is a continuation-in-part of Ser. No. US 94-323755,
filed on 14 Oct 1994, now patented, Pat. No. US 5475110
DT Utility
LN.CNT 3770
INCL INCLM: 514/338.000
INCLS: 514/131.000; 514/140.000
NCL NCLM: 514/338.000
NCLS: 514/339.000; 514/410.000
IC [6]
ICM: A61K031-40
EXF 514/410; 514/338; 514/339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 44 kwic

L6 ANSWER 44 OF 73 USPATFULL
TI Method for administering neurologic agents to the **brain**
AB Disclosed is a method for transporting neurologic therapeutic
agents to the **brain** by means of the olfactory neural
pathway and a pharmaceutical composition useful in the treatment
of **brain** disorders.
SUMM The present invention is directed to a method for delivering
neurologic agents to the **brain** by means of the olfactory
neural pathway and a pharmaceutical composition useful in the
treatment of **brain** disorders.
SUMM Alzheimer's disease is an age-associated neurodegenerative
disorder of the **brain**. The disorder is characterized
histopathologically by the formation and accumulation of
neurofibrillary tangles and neuritic plaques in the **brain**
. In particular, pathological changes associated with the disease
extensively affect neurons in the olfactory bulb and its connected
brain structures. Degeneration with loss of neurons has
been observed in the hippocampal formation, amygdaloid nuclei,
nucleus basalis of Meynert, locus ceruleus, and the
brainstem raphe nuclei, all of which project to the
olfactory bulb. These degenerative changes result in the loss of
memory and. . .
SUMM At present, there is no treatment for Alzheimer's disease which
effectively prevents or retards the progressive neurodegeneration
of the **brain** and the loss of smell and cognitive decline
associated with the illness. Neurotrophic and neuritogenic
factors, such as nerve growth. . .
SUMM Neurotrophic and neuritogenic factors are agents that affect the
survival and differentiation of neurons in the peripheral and
central nervous systems. These growth promoting
factors are signaling substances that are synthesized in tissues
in response to neurons capable of responding. . . receptors on
axon terminals, and can be internalized and retrogradely
transported to the cell body of neurons. See M. Seiler,
Brain Res. 300:33-39 (1984). Other naturally-occurring
nerve growth promoting factors include gangliosides,
phosphatidylserine (PS), **brain**-derived neurotrophic
factor, fibroblast **growth factor**, **insulin**, **insulin**-like **growth factors**, ciliary neurotrophic factor and glia-derived
nexin.
SUMM Testing the effectiveness of potentially therapeutic agents
against **brain** disease in animal toxicity studies and
human trials has been hindered, however, by the inability of
existing procedures to readily deliver adequate levels of the
agent to affected areas of the **brain** over an extended
period of time.

SUMM Some experimental therapeutic agents used in the treatment of Alzheimer's disease, such as GM-1 ganglioside, can be administered to the **brain** through the bloodstream because of their ability to traverse the blood-**brain** barrier. However, it is not clear that effective levels of the ganglioside reach the affected areas of the **brain**.

SUMM Other potentially therapeutic agents, such as nerve growth factor (NGF), are unable to cross the blood-**brain** barrier and must be administered to the **brain** by other means. One such method of delivery is by an intracerebroventricular pump. Use of such a pump, however, necessitates. . . complications. Furthermore, administration of medication by pump does not facilitate selective delivery of medication solely to those areas of the **brain** affected by disease. Consequently, healthy areas of the **brain** may be adversely affected by the neurologic agent while some diseased areas may not receive a high enough level for. . .

SUMM An effective method of therapeutic intervention is needed to prevent and effectively treat **brain** diseases such as Alzheimer's disease, Parkinson's disease, nerve damage from cerebrovascular disorders such as **stroke**, and ordinary aging. Testing the potential of various neurologic agents is an important aspect of developing treatments for neurodegenerative diseases. Since existing methods of testing possible therapeutic agents and treating **brain** disorders are of limited benefit, a goal of the present invention is to develop a procedure to effectively deliver neurologic agents to the **brain**. A particular goal of the invention is to develop a method of delivering neurologic substances to the **brain** to augment the level of activity against **brain** diseases by naturally-occurring substances. A further goal is to develop a means of selective delivery of a neurologic agent only to areas of the **brain** which are damaged by a **brain** disorder. Still another objective is to develop a composition that can cause absorption of the neurologic agent into olfactory neurons and along the olfactory neural pathway to damaged neurons in the **brain**. Another goal is to provide prophylactic treatment of neurodegenerative diseases and to treat and/or prevent associated loss of smell.

SUMM . . . other goals are met by the present invention which is directed to a method to convey therapeutic substances to the **brain** for the treatment of neurologic or psychiatric disorders and a pharmaceutical composition capable of delivering a neurologic agent to the **brain** for use in such a method of treatment. More specifically, the method of medical treatment involves intranasal administration of a neurologic agent which may be absorbed into the olfactory system of the **brain** for the treatment of **brain** disorders such as Alzheimer's disease, Parkinson's disease, affective disorders such as depression and mania, nerve damage from cerebrovascular disorders such as **stroke**, and the like.

SUMM . . . neurologic substance is administered to the nasal cavity of a patient affected with Alzheimer's disease or other disease afflicting the **brain**. The neurologic factor may be applied alone or in combination with other substances. Particular formulations may include the neurologic substance. . . of the neurologic agent through the nasal mucosa and/or along the olfactory neural pathway to damaged nerve cells of the **brain**.

SUMM . . . the invention may employ transneuronal anterograde and retrograde transport of the neurologic agent entering through the olfactory system of the **brain**. Once the agent is dispensed into the nasal cavity, the agent may transport through the nasal mucosa by means of the peripheral olfactory neurons into the olfactory bulb and interconnected areas of the **brain** such as the hippocampal formation, amygdaloid nuclei, nucleus basalis of Meynert, locus ceruleus, and the **brainstem** raphe nuclei. The agent alone may facilitate this movement into the **brain**. Alternatively, the carrier and/or other transfer-promoting factors may assist in the transport of the neurologic agent into and along the. . .

SUMM . . . of nerve growth promoting factors to peripheral nerve cells of the olfactory system, a purported entryway for causative agents of **brain** diseases, helps protect against disease in these nerve cells and regenerate injured nerve cells thereby forestalling the subsequent spread of disease to susceptible areas of the **brain**.

SUMM . . . to naturally occurring nerve growth promoting substances.
Among the preferred neurologic agents are gangliosides,
phosphatylserine (PS), nerve growth factor (NGF), **brain**
-derived neurotrophic factor, fibroblast **growth**
factor, insulin, insulin-like
growth factors, ciliary neurotrophic factor,
glia-derived nexin, and cholinergic enhancing factors such as
phosphoethanolamine and thyroid hormone T.3. GM-1 ganglioside and
nerve. . .
DETD . . . neurologic agent to the nasal cavity of a human or other
mammal for the testing of potential therapeutic agents against
brain disease and for the treatment of **brain**
disorders such as Alzheimer's disease, Parkinson's disease,
affective disorders such as depression and mania, nerve damage
from cerebrovascular disorders such as **stroke**, or
ordinary aging. In particular, the method delivers a neurologic
agent to diseased areas of the **brain** by means of the
olfactory neural pathway. The method may employ a pharmaceutical
composition capable of transporting the neurologic agent to
diseased neurons of the **brain**.
DETD The method of the invention may achieve delivery of neurologic
substances to afflicted areas of the **brain** through
transneuronal retrograde and anterograde transport mechanisms.
Delivery of neurologic agents to the **brain** by that
transport system may be achieved in several ways. One technique
comprises delivering the neurologic agent alone to the. . .
nasal cavity. In this instance, the chemical characteristics of
the agent itself facilitate its transport to diseased neurons in
the **brain**. Alternatively, the agent may be combined with
other substances that assist in transporting the agent to sites of
damaged neurons.. . . substances are capable of delivering the
agent to peripheral sensory neurons and/or along neural pathways
to dysfunctioning areas of the **brain**. It is further
preferred that the peripheral nerve cells of the olfactory neural
pathway be utilized in order to deliver the neurologic agent to
damaged neurons in those regions of the **brain** that are
connected to the olfactory bulb.
DETD . . . be applied in non-toxic levels in order to provide an
effective level of activity within the neural system against the
brain disease. It is further preferred that the neurologic
agent promote nerve cell growth and survival or augment the
activity of. . . other adjuvants to form a pharmaceutical
composition. Among the preferred neurologic agents are
gangliosides, nerve growth factor (NGF), phosphatidylserine (PS),
brain-derived neurotrophic factor, fibroblast
growth factor, insulin,
insulin-like **growth factors**, ciliary
neurotrophic factor, glia-derived nexin, and cholinergic enhancing
factors such as phosphoethanolamine and thyroid hormone T.3. Among
those agents that. . .
DETD . . . olfactory neurons rather than the capillaries within the
respiratory epithelium. The invention prefers the transport of
neurologic agents to the **brain** by means of the nervous
system instead of the circulatory system so that potentially
therapeutic agents that are unable to cross the blood-
brain barrier from the bloodstream into the **brain**
may be delivered to damaged neurons in the **brain**.
DETD . . . the absorption of the agent into the peripheral olfactory
receptor cells. These peripheral neurons provide a direct
connection between the **brain** and the outside environment
due to their role in odor detection.
DETD The invention also provides a means for the prevention of
brain disorders particularly in cases where the causative
factor enters the **brain** through olfactory neurons. It is
preferred that prophylactic treatments be employed where evidence
indicates neuronal degeneration in the olfactory neurons as in the
case of Alzheimer's disease and other related **brain**
disorders. Prophylactic treatment of **brain** disease may
involve the direct or indirect application of neurologic
therapeutic agents to the olfactory epithelium. Such agents may
be. . .
DETD . . . the absorption of the agent into the olfactory neurons.
Potential neurologic agents include gangliosides, nerve growth
factor (NGF), phosphatidylserine (PS), **brain**-derived
neurotrophic factor, fibroblast **growth factor,**
insulin, insulin-like **growth**
factors, ciliary neurotrophic factor, glia-derived nexin,
and cholinergic enhancing factors such as phosphoethanolamine and
thyroid hormone T.3. GM-1 ganglioside and nerve growth factor

(NGF) are among those agents that are particularly preferred for
prophylactic treatment of **brain** disorders.
DETD . . . further directed to a pharmaceutical composition
comprising an amount of a neurologic agent which is effective in
treating or preventing **brain** disorders in a mammal, when
administered thereto, in combination with a pharmaceutically-
acceptable vehicle such as a liquid or powdered carrier. . .
DETD . . . such as synthesizing neurotransmitter substances. Among
the neurologic agents that are preferred are nerve growth factor
(NGF), gangliosides, phosphatidylserine (PS), **brain**
-derived neurotrophic factor, fibroblast **growth**
factor, insulin, insulin-like
growth factors, ciliary neurotrophic factor,
glia-derived nexin, and cholinergic enhancing factors such as
phosphoethanolamine and thyroid hormone T.3.
DETD . . . pharmaceutical composition are lipophilic substances that
may enhance absorption of the agent across the nasal membrane and
delivery to the **brain** by means of the olfactory neural
pathway. The neurologic agent may be mixed with a lipophilic
adjuvant alone or in. . .
DETD The present invention for a method of administering neurologic
agents useful in the treatment of **brain** disorders such
as Alzheimer's disease presents several advantages over currently
available methods.
DETD . . . the present invention prefers the olfactory neural
pathway rather than the bloodstream to deliver agents useful for
the treatment of **brain** disorders such as Alzheimer's
disease directly to the **brain**. Use of the olfactory
system to transport a neurologic agent to the **brain**
obviates the blood-**brain** barrier so that medications
like nerve growth factor (NGF), a protein that cannot normally
cross that barrier, can be delivered directly to the **brain**
. Although the agent that is administered may be absorbed into the
bloodstream as well as the olfactory neural pathway, the. . .
in fluids present in the bloodstream. As such, the invention
provides an improved method of testing potential therapeutic
agents against **brain** disease and of treating
neurodegenerative disorders.
DETD . . . of the intranasal administration of the medication. The
olfactory system provides a direct connection between the outside
environment and the **brain** thus providing quick and ready
delivery of neurologic agents for treatment of neurologic
disorders. Moreover, the means of applying a. . .
DETD The application of a neurologic therapeutic agent to the nasal
epithelium also helps prevent the spread of certain **brain**
disorders by directly treating peripheral olfactory neurons that
are injured by neurotoxins and other insults. Prophylactic
treatment of these outlying nerve cells helps preclude the
entrance of disease-causing agents into the **brain**. This
method of treatment is particularly beneficial in cases of
Alzheimer's disease where an environmental factor is suspected of
being. . .
DETD Another advantage of the invention is that it provides delivery of
neurologic agents solely to those areas of the **brain**
affected by disease while avoiding unwanted treatment of
brain regions which are free of the disease. The method of
the invention employs a neurologic agent or other substance that
has an affinity for neuron receptor sites in order to facilitate
delivery of the agent directly to the **brain** through the
olfactory epithelium.
CLM What is claimed is:
1. A method for delivering a neurologic therapeutic agent to the
brain of a mammal, comprising: applying an effective
amount of the neurologic therapeutic agent directly to the
olfactory epithelium of the. . . an effective amount of
lipophilic micelles, or a combination thereof; the neurologic
agent being unable to be delivered to the **brain** from the
circulatory system of the mammal by crossing the blood-
brain barrier of the mammal; wherein the neurologic agent
is absorbed through the olfactory epithelium of the nasal mucosa
into olfactory neurons and an effective amount of the agent is
transported into the **brain** of the mammal by means of the
olfactory neural pathway to provide a protective effect on
brain cells against **stroke**.
4. The method according to claim 1 wherein the agent is
transported to the hippocampal formation, amygdaloid nuclei,
nucleus basalis of Meynert, locus ceruleus, **brainstem**
raphe nuclei, or any combination thereof.

5. The method according to claim 1 wherein the agent is transported to damaged neurons in the **brain**.

8. A method for delivering a neurologic therapeutic agent to the **brain** of a mammal, comprising: applying an effective amount of the neurologic therapeutic agent directly to the olfactory epithelium of the. . . an effective amount of lipophilic micelles, or a combination thereof; the neurologic agent being unable to be delivered to the **brain** from the circulatory system of the mammal by crossing the blood-**brain** barrier of the mammal; wherein the neurologic agent is absorbed through the olfactory epithelium of the nasal mucosa into olfactory neurons and an effective amount of the agent is transported into the **brain** of the mammal by means of the olfactory neural pathway to inhibit degeneration of nerve cells in the **brain**.

9. The method according to claim 8, wherein the **brain** cells are basal forebrain cholinergic neurons.

=> d 30-39

L6 ANSWER 30 OF 73 USPATFULL
AN 97:73601 USPATFULL
TI Compositions for inhibiting restenosis
IN Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadephia, PA, United States (U.S. corporation)
PI US 5658894 970819
AI US 94-345011 941123 (8)
RLI Continuation of Ser. No. US 92-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 91-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 89-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US -900592 which is a continuation-in-part of Ser. No. US 90-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
LN.CNT 1449
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 536/103.000; 530/810.000; 530/812.000; 530/813.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 530/810.000; 530/812.000; 530/813.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 536/103; 530/810; 530/812; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 73 USPATFULL
AN 97:68499 USPATFULL
TI Methods and compositions for stimulating neurite growth
IN Armistead, David M., Maynard, MA, United States
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
PI US 5654332 970805
AI US 95-486004 950608 (8)
DT Utility
LN.CNT 1225
INCL INCLM: 514/533.000
INCLS: 514/534.000; 514/330.000; 514/423.000; 514/428.000; 514/438.000; 514/538.000; 514/547.000; 514/549.000; 514/551.000; 514/465.000; 514/466.000
NCL NCLM: 514/533.000
NCLS: 514/330.000; 514/423.000; 514/428.000; 514/438.000; 514/465.000; 514/466.000; 514/534.000; 514/538.000; 514/547.000; 514/549.000; 514/551.000
IC [6]
ICM: A61K031-235
ICS: A61K031-24; A61K031-40; A61K031-38; A61K031-44; A61K031-225; A61K031-22; A61K031-36
EXF 514/533; 514/534; 514/330; 514/423; 514/428; 514/438; 514/538; 514/547; 514/549; 514/551; 514/465; 514/466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 73 USPATFULL
AN 97:68346 USPATFULL
TI Secreted proteins and polynucleotides encoding them
IN Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaVallie, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PA Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5654173 970805

AI US 96-702080 960823 (8)
DT Utility
LN.CNT 1685
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/326.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/326.000; 536/023.500
IC [6]
ICM: C12P021-02
ICS: C12N001-21; C12N005-10; C07H021-04
EXF 435/69.1; 435/326; 435/252.3; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 73 USPATFULL
AN 97:66223 USPATFULL
TI OP-3-induced morphogenesis
IN Oppermann, Hermann, Medway, MA, United States
Ozkaynak, Engin, Milford, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Rueger, David C., Hopkinton, MA, United States
Pang, Roy H. L., Etna, NH, United States
Cohen, Charles M., Medway, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)
PI US 5652337 970729
AI US 95-479666 950607 (8)
RLI Division of Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-922813, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-752764, filed on 31 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-923780, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-752764, filed on 30 Aug 1991, now abandoned And a continuation-in-part of Ser. No. US 91-752857, filed on 30 Aug 1991, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-938336, filed on 28 Aug 1992, now abandoned And a continuation-in-part of Ser. No. US 92-938337, filed on 28 Aug 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-753059, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-938021, filed on 28 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-752861, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-945285, filed on 15 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 92-945286, filed on 15 Sep 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-752764, filed on 30 Aug 1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-946235, filed on 16 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 92-946238, filed on 16 Sep 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-752764, filed on 30 Aug 1991, now abandoned
DT Utility
LN.CNT 2887
INCL INCLM: 530/350.000
INCLS: 530/399.000
NCL NCLM: 530/350.000
NCLS: 530/399.000
IC [6]
ICM: C07K019-51
EXF 530/350; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 73 USPATFULL
AN 97:66103 USPATFULL
TI Treating disorders by application of **insulin**-like **growth factors** and analogs
IN Lewis, Michael E., West Chester, PA, United States
Kauer, James C., Kennett Square, PA, United States
Smith, Kevin R., Parkesburg, PA, United States
Callison, Kathleen V., Merchantville, NJ, United States
Baldino, Frank, Landenberg, PA, United States
Neff, Nicola, Wallingford, PA, United States
Iqbal, Mohamed, Malvern, PA, United States
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
PI US 5652214 970729
AI US 92-958903 921007 (7)

RLI Continuation-in-part of Ser. No. US 92-869913, filed on 15 Apr
1992, now abandoned which is a continuation-in-part of Ser. No. US
90-534139, filed on 5 Jun 1990, now abandoned which is a
continuation-in-part of Ser. No. US 89-361595, filed on 5 Jun
1989, now patented, Pat. No. US 5093317
DT Utility
LN.CNT 2358
INCL INCLM: 514/012.000
INCLS: 514/021.000
NCL NCLM: 514/012.000
NCLS: 514/021.000
IC [6]
ICM: A61K038-30
EXF 514/12; 514/9; 514/11; 514/2; 514/3; 514/21; 530/317; 530/324;
530/303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 73 USPATFULL
AN 97:66010 USPATFULL
TI Nucleic acid encoding a novel morphogenic protein, OP-3
IN Ozkaynak, Engin, Milford, MA, United States
Oppermann, Hermann, Medway, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)
PI US 5652118 970729
AI US 95-480528 950607 (8)
RLI Continuation of Ser. No. US 92-971091, filed on 3 Nov 1992, now
abandoned which is a continuation-in-part of Ser. No. US
92-922813, filed on 31 Jul 1992, now abandoned which is a
continuation-in-part of Ser. No. US 91-752764, filed on 31 Aug
1991, now abandoned which is a continuation-in-part of Ser. No. US
91-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US
92-971091, filed on 3 Nov 1992, now abandoned which is a
continuation-in-part of Ser. No. US 92-923780, filed on 31 Jul
1992, now abandoned which is a continuation-in-part of Ser. No. US
91-752764, filed on 30 Aug 1991, now abandoned And a
continuation-in-part of Ser. No. US 91-752857, filed on 30 Aug
1991, now abandoned , each Ser. No. US - which is a
continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar
1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov
1992, now abandoned which is a continuation-in-part of Ser. No. US
92-938336, filed on 28 Aug 1992, now abandoned And a
continuation-in-part of Ser. No. US 92-938337, filed on 28 Aug
1992, now abandoned , each Ser. No. US - which is a
continuation-in-part of Ser. No. US 91-753059, filed on 30 Aug
1991, now abandoned which is a continuation-in-part of Ser. No. US
91-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US
92-971091, filed on 3 Nov 1992, now abandoned which is a
continuation-in-part of Ser. No. US 92-938021, filed on 28 Aug
1992, now abandoned which is a continuation-in-part of Ser. No. US
91-752861, filed on 30 Aug 1991, now abandoned which is a
continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar
1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov
1992, now abandoned which is a continuation-in-part of Ser. No. US
92-945285, filed on 15 Sep 1992, now abandoned And a
continuation-in-part of Ser. No. US 92-945286, filed on 15 Sep
1992, now abandoned , each Ser. No. US - which is a
continuation-in-part of Ser. No. US 91-752764, filed on 30 Aug
1991, now abandoned , said Ser. No. US 92-971091, filed on 3 Nov
1992, now abandoned which is a continuation-in-part of Ser. No. US
92-946235, filed on 16 Sep 1992, now abandoned And a
continuation-in-part of Ser. No. US 92-946238, filed on 16 Sep
1992, now abandoned , each Ser. No. US - which is a
continuation-in-part of Ser. No. US 91-252764, filed on 30 Aug
1991, now abandoned
DT Utility
LN.CNT 3004
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/252.330; 435/070.100; 435/070.300;
435/071.100; 435/071.200; 435/320.100; 435/172.300;
435/325.000; 435/348.000; 435/358.000; 435/360.000;
435/365.100; 435/366.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/070.100; 435/070.300; 435/071.100; 435/071.200;
435/172.300; 435/252.300; 435/252.330; 435/320.100;
435/325.000; 435/348.000; 435/358.000; 435/360.000;
435/365.100; 435/366.000; 536/023.500
IC [6]
ICM: C12N005-10
ICS: C12N015-12; C12N015-63; C07H021-04
EXF 435/69.1; 435/240.2; 435/320.1; 435/252.3; 435/252.33; 435/70.1;
435/70.3; 435/71.1; 435/71.2; 435/172.3; 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 73 USPATFULL
AN 97:63766 USPATFULL
TI Methods for in vivo delivery of nutriceuticals and compositions
useful therefor

IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champagne, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champagne, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)
PI US 5650156 970722
AI US 95-482272 950607 (8)
RLI Continuation-in-part of Ser. No. US 94-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 93-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And Ser. No. US 93-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
LN.CNT 3310
INCL INCLM: 424/400.000
INCLS: 424/450.000; 424/451.000; 424/056.000; 424/009.400; 424/009.500; 424/009.300
NCL NCLM: 424/400.000
NCLS: 424/009.300; 424/009.400; 424/009.500; 424/056.000; 424/450.000; 424/451.000
IC [6]
ICM: A61K009-00
EXF 424/400; 424/450; 424/451; 424/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 73 USPATFULL
AN 97:61667 USPATFULL
TI Methods of treatment using ciliary neurotrophic factor
IN Davis, Samuel, New York, NY, United States
Squinto, Stephen P., Irvington, NY, United States
Furth, Mark E., Pelham, NY, United States
Yancopoulos, George D., Briarcliff Manor, NY, United States
PA Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S. corporation)
PI US 5648334 970715
AI US 95-449329 950524 (8)
RLI Division of Ser. No. US 93-1904, filed on 7 Jan 1993, now abandoned which is a continuation of Ser. No. US 91-700677, filed on 15 May 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-676647, filed on 28 Mar 1991, now patented, Pat. No. US 5426177 which is a continuation-in-part of Ser. No. US 90-532285, filed on 1 Jun 1990, now abandoned
DT Utility
LN.CNT 2326
INCL INCLM: 514/012.000
INCLS: 514/002.000; 530/350.000; 530/399.000
NCL NCLM: 514/012.000
NCLS: 514/002.000; 530/350.000; 530/399.000
IC [6]
ICM: A61K038-17
ICS: C07K014-475
EXF 514/2; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 73 USPATFULL
AN 97:54233 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5641783 970624
AI US 94-303842 940908 (8)
RLI Continuation-in-part of Ser. No. US 93-152650, filed on 12 Nov 1993 And Ser. No. US 93-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
DT Utility
LN.CNT 3206
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000; 514/247.000; 514/248.000; 514/249.000; 514/255.000; 514/256.000; 514/258.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000; 514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000; 514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/381.000; 514/383.000; 514/389.000; 514/394.000; 514/395.000; 514/398.000; 514/399.000; 514/401.000; 514/404.000; 514/406.000; 514/413.000; 514/415.000; 514/416.000; 514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000; 514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000;

544/067.000; 544/090.000;
544/091.000; 544/162.000;
544/215.000; 544/216.000;
544/219.000; 544/220.000;
544/224.000; 544/235.000;
544/239.000; 544/254.000;
544/255.000; 544/257.000;
544/262.000; 544/272.000;
544/277.000; 544/278.000;
544/280.000; 544/283.000;
544/286.000; 544/301.000;
544/311.000; 544/335.000;
544/336.000; 544/350.000;
544/353.000; 544/385.000;
544/401.000; 546/102.000;
546/113.000; 546/114.000;
546/115.000; 546/117.000;
546/118.000; 546/119.000;
546/122.000; 546/138.000;
546/139.000; 546/150.000;
546/153.000; 546/157.000;
546/164.000; 546/176.000;
546/178.000; 546/242.000;
546/243.000; 546/246.000;
546/264.000; 546/300.000;
546/334.000; 548/100.000;
548/123.000; 548/125.000;
548/127.000; 548/128.000;
548/131.000; 548/134.000;
548/146.000; 548/153.000;
548/179.000; 548/186.000;
548/207.000; 548/214.000;
548/215.000; 548/217.000;
548/221.000; 548/225.000;
548/228.000; 548/229.000;
548/235.000; 548/237.000;
548/240.000; 548/241.000;
548/243.000; 548/247.000;
548/252.000; 548/267.200;
548/267.800; 548/303.700;
548/306.400; 548/307.100;
548/309.700; 548/319.100;
548/323.500; 548/340.100;
548/348.100; 548/349.100;
548/356.100; 548/370.100;
548/375.100; 548/379.400;
548/452.000; 548/453.000;
548/470.000; 548/482.000;
548/485.000; 548/486.000;
548/491.000; 548/503.000;
548/532.000; 548/543.000;
548/546.000; 548/550.000;
548/565.000; 548/566.000
NCL NCLM: 514/263.000
NCLS: 514/183.000; 514/222.500;
514/223.500; 514/224.200;
514/226.800; 514/227.500;
514/228.800; 514/229.200;
514/230.500; 514/230.800;
514/237.800; 514/241.000;
514/242.000; 514/243.000;
514/246.000; 514/247.000;
514/248.000; 514/249.000;
514/255.000; 514/256.000;
514/258.000; 514/259.000;
514/261.000; 514/262.000;
514/270.000; 514/274.000;
514/297.000; 514/300.000;
514/301.000; 514/302.000;
514/303.000; 514/306.000;
514/307.000; 514/311.000;
514/312.000; 514/315.000;
514/345.000; 514/351.000;
514/357.000; 514/359.000;
514/360.000; 514/361.000;
514/362.000; 514/363.000;
514/364.000; 514/365.000;
514/367.000; 514/369.000;
514/372.000; 514/373.000;
514/374.000; 514/375.000;
514/376.000; 514/378.000;
514/379.000; 514/380.000;
514/381.000; 514/383.000;
514/389.000; 514/394.000;
514/395.000; 514/398.000;
514/399.000; 514/401.000;
514/404.000; 514/406.000;
514/413.000; 514/415.000;
514/416.000; 514/418.000;
514/423.000; 514/424.000;
514/425.000; 514/427.000;
514/428.000; 544/001.000;
544/002.000; 544/003.000;
544/008.000; 544/053.000;
544/063.000; 544/065.000;
544/066.000; 544/067.000;
544/090.000; 544/091.000;
544/162.000; 544/215.000;
544/216.000; 544/219.000;
544/220.000; 544/224.000;
544/235.000; 544/239.000;
544/254.000; 544/255.000;
544/257.000; 544/262.000;
544/272.000; 544/277.000;
544/278.000; 544/280.000;
544/283.000; 544/286.000;
544/301.000; 544/311.000;
544/335.000; 544/336.000;
544/350.000; 544/353.000;
544/385.000; 544/401.000;
546/102.000; 546/113.000;
546/114.000; 546/115.000;
546/117.000; 546/118.000;
546/119.000; 546/122.000;
546/138.000; 546/139.000;
546/150.000; 546/153.000;
546/157.000; 546/164.000;
546/176.000; 546/178.000;
546/242.000; 546/243.000;
546/246.000; 546/264.000;
546/300.000; 546/334.000;
548/100.000; 548/123.000;
548/125.000; 548/127.000;
548/128.000; 548/131.000;
548/134.000; 548/146.000;
548/153.000; 548/179.000;
548/186.000; 548/207.000;
548/214.000; 548/215.000;
548/217.000; 548/221.000;
548/225.000; 548/228.000;
548/229.000; 548/235.000;
548/237.000; 548/240.000;
548/241.000; 548/243.000;
548/247.000; 548/252.000;
548/267.200; 548/267.800;
548/303.700; 548/306.400;
548/307.100; 548/309.700;
548/319.100; 548/323.500;
548/340.100; 548/348.100;
548/349.100; 548/356.100;
548/370.100; 548/375.100;
548/379.400; 548/452.000;
548/453.000; 548/470.000;
548/482.000; 548/485.000;
548/486.000; 548/491.000;
548/503.000; 548/532.000;
548/543.000; 548/546.000;
548/550.000; 548/565.000;
548/566.000

IC [6]
ICM: A61K031-415
ICS: A61K031-42; A61K031-425; A61K031-52
EXF 544/272; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 73 USPATFULL
AN 97:54200 USPATFULL
TI Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
IN Louis, Jean-Claude, Thousand Oaks, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 5641750 970624
AI US 95-564833 951129 (8)
DT Utility
LN.CNT 2005
INCL INCLM: 514/012.000
INCLS: 435/069.100; 435/069.400
NCL NCLM: 514/012.000
NCLS: 435/069.100; 435/069.400
IC [6]
ICM: A61F002-00
ICS: A61K047-00; A61K031-685
EXF 514/12; 435/69.1; 435/69.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus medline

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
83.65 121.60

FILE 'CAPLUS' ENTERED AT 20:21:20 ON 26 APR 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 20:21:20 ON 26 APR 1998

=> s l4

L7 53 L4

=> e ishii d/au

E1 7 ISHII CHIZU/AU
E2 1 ISHII CLIFF/AU
E3 87 --> ISHII D/AU
E4 57 ISHII D N/AU
E5 227 ISHII DAIDO/AU
E6 1 ISHII DEISUKE/AU
E7 1 ISHII DOUBLAS N/AU
E8 2 ISHII DOUGLAS/AU
E9 39 ISHII DOUGLAS N/AU
E10 134 ISHII E/AU
E11 3 ISHII E K/AU
E12 7 ISHII E L/AU

=> s (e3-4 or e7-9) and igf?

L8 43 (("ISHII D"/AU OR "ISHII D N"/AU) OR ("ISHII DOUBLAS N"/AU OR "ISHII DOUGLAS"/AU OR "ISHII DOUGLAS N"/AU)) AND IGF?

=> d 1-43

L8 ANSWER 1 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1997:674681 CAPLUS
DN 127:342187
TI Insulin-like growth factor (**IGF**) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and **IGF** treatment ameliorates diabetic neuropathy
AU Zhuang, Hui-Xin; Wuarin, Laura; Fei, Zhi-Jian; **Ishii, Douglas N.**
CS Department of Physiology and Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, USA
SO J. Pharmacol. Exp. Ther. (1997), 283(1), 366-374
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English

L8 ANSWER 2 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1997:511653 CAPLUS
DN 127:104818
TI Method for effecting changes in the central nervous system by administration of **IGF**-I or **IGF**-II
IN **Ishii, Douglas N.**
PA Colorado State University Research Foundation, USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
PI WO 9721449 A1 970619
DS W: CA, CN, JP, PL
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 96-US19663 961211
PRAI US 95-571802 951213
DT Patent
LA English

L8 ANSWER 3 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1997:371022 CAPLUS
DN 127:60676
TI Roles of insulin-like growth factors in peripheral nerve regeneration and motor neuron survival
AU **Ishii, D. N.**; Pu, S. F.; Glazner, G. W.; Zhuang, H.-X.; Marsh, D. J.
CS Department Physiology, Department Biochemistre Molecular Biology, Colorado State University, Fort Collins, CO, 80523, USA
SO Chem. Factors Neural Growth, Degener. Repair (1996), 399-421.
Editor(s): Bell, Christopher. Publisher: Elsevier, Amsterdam, Neth.
CODEN: 64MUAK
DT Conference; General Review
LA English

L8 ANSWER 4 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1996:511170 CAPLUS
DN 125:186579
TI Insulin-like growth factors reverse or arrest diabetic neuropathy:
Effects on hyperalgesia and impaired nerve regeneration in rats
AU Zhuang, Hui-Xin; Snyder, Cynthia K.; Pu, Su-Fen; **Ishii, Douglas N.**
CS Department Physiology, Colorado State University, Fort Collins, CO, 80523, USA
SO Exp. Neurol. (1996), 140(2), 198-205
CODEN: EXNEAC; ISSN: 0014-4886
DT Journal
LA English

L8 ANSWER 5 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1996:454059 CAPLUS
DN 125:139592
TI Brain insulin-like growth factor-II mRNA content is reduced in
insulin-dependent and non-insulin-dependent diabetes mellitus
AU Wuarin, Laura; Namdev, Ritu; Burns, J. Gregory; Fei, Zhi-Jian;
Ishii, Douglas N.
CS Departments of Physiology and Biochemistry and Molecular Biology,
Colorado State University, Fort Collins, CO, 80523, USA
SO J. Neurochem. (1996), 67(2), 742-751
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English

L8 ANSWER 6 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1995:934824 CAPLUS
DN 124:1406
TI Differential spatio-temporal expression of the insulin-like growth
factor genes in regenerating sciatic nerve
AU Pu, Su-Fen; Zhuang, Hui-Xin; **Ishii, Douglas N.**
CS Department of Physiology and Department of Biochemistry and
Molecular Biology, Colorado State University, Fort Collins, CO, 80523, USA
SO Mol. Brain Res. (1995), 34(1), 18-28
CODEN: MBREE4; ISSN: 0169-328X
DT Journal
LA English

L8 ANSWER 7 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1995:386789 CAPLUS
DN 122:184587
TI Early reduction in insulin-like growth factor gene expression in
diabetic nerve
AU Wuarin, Laura; Guertin, Diane M.; **Ishii, Douglas N.**
CS Department of Physiology, Colorado State University, Fort Collins,
CO, 80523, USA
SO Exp. Neurol. (1994), 130(1), 106-14
CODEN: EXNEAC; ISSN: 0014-4886
DT Journal
LA English

L8 ANSWER 8 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1995:323050 CAPLUS
DN 122:97171
TI Insulin-like growth factors protect against diabetic neuropathy:
effects on sensory nerve regeneration in rats
AU **Ishii, D. N.**; Lupien, S. B.
CS Departments Physiol. Biochem. Mol. Biol., Colorado State Univ., Fort
Collins, CO, USA
SO J. Neurosci. Res. (1995), 40(1), 138-44
CODEN: JNREDK; ISSN: 0360-4012
DT Journal
LA English

L8 ANSWER 9 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1995:235660 CAPLUS
DN 122:7052
TI Reduced insulin-like growth factor-I mRNA content in liver, adrenal
glands and spinal cord of diabetic rats
AU **Ishii, D.N.**; Guertin, D.M.; Whalen, L.R.
CS Department of Physiology, Colorado State University, Fort Collins,
CO, 80523, USA
SO Diabetologia (1994), 37(11), 1073-81
CODEN: DBTGAJ; ISSN: 0012-186X
DT Journal
LA English

L8 ANSWER 10 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1994:622051 CAPLUS
DN 121:222051
TI Role of insulin-like growth factors in peripheral nerve regeneration
AU **Ishii, D. N.**; Glazner, G. W.; Pu, S.-F.
CS Department of Physiology, Colorado State University, Fort Collins,
CO, 80523, USA
SO Pharmacol. Ther. (1994), 62(1-2), 125-44
CODEN: PHTHDT; ISSN: 0163-7258
DT Journal; General Review
LA English

L8 ANSWER 11 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1994:596717 CAPLUS
DN 121:196717
TI Elevated insulin-like growth factor (**IGF**) gene expression
in sciatic nerves during **IGF**-supported nerve regeneration
AU Glazner, Gordon W.; Morrison, Andrew E.; **Ishii, Douglas N.**
CS Department of Physiology and, Fort Collins, CO, 80523, USA
SO Mol. Brain Res. (1994), 25(3-4), 265-72
CODEN: MBREE4; ISSN: 0169-328X
DT Journal
LA English

L8 ANSWER 12 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1993:662607 CAPLUS
DN 119:262607
TI Regulation of peripheral nerve regneration by insulin-like growth

factors
AU **Ishii, Douglas N.**; Glazner, Gordon W.; Whalen, L. Raymond
CS Dep. Physiol., Colorad State Univ., Fort Collins, CO, 80523, USA
SO Ann. N. Y. Acad. Sci. (1993), 692(Role of Insulin-like Growth
Factors in the Nervous System), 172-82
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal; General Review
LA English

L8 ANSWER 13 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1993:487255 CAPLUS
DN 119:87255
TI Insulin-like growth factor II increases the rate of sciatic nerve
regeneration in rats
AU Glazner, G. W.; Lupien, S.; Miller, J. A.; **Ishii, D. N.**
CS Dep. Physiol., Colorado State Univ., Fort Collins, CO, 80523, USA
SO Neuroscience (Oxford) (1993), 54(3), 791-7
CODEN: NRSCDN; ISSN: 0306-4522
DT Journal
LA English

L8 ANSWER 14 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1993:183474 CAPLUS
DN 118:183474
TI Neurobiology of insulin and insulin-like growth factors
AU **Ishii, Doublas N.**
CS Dep. Physiol., Colorado State Univ., Fort Collins, CO, 80523, USA
SO Neurotrophic Factors (1993), 415-42. Editor(s): Loughlin, Sandra
E.; Fallon, James H. Publisher: Academic, San Diego, Calif.
CODEN: 58VKAI
DT Conference; General Review
LA English

L8 ANSWER 15 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1993:74365 CAPLUS
DN 118:74365
TI Insulin-like growth factor II stimulates motor nerve regeneration
AU Near, Stephanie L.; Whalen, L. Raymond; Miller, James A.;
Ishii, Douglas N.
CS Dep. Anat. Neurobiol., Colorado State Univ., Fort Collins, CO,
80523, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1992), 89(24), 11716-20
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English

L8 ANSWER 16 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1992:421120 CAPLUS
DN 117:21120
TI Effects of insulin and insulin-like growth factors on neurofilament
mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells
AU Wang, C.; Li, Y.; Wible, B.; Angelides, K. J.; **Ishii, D. N.**
CS Dep. Physiol., Colorado State Univ., Fort Collins, CO, 80523, USA
SO Mol. Brain Res. (1992), 13(4), 289-300
CODEN: MBREE4; ISSN: 0169-328X
DT Journal
LA English

L8 ANSWER 17 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1992:99392 CAPLUS
DN 116:99392
TI Second messengers mediating gene expression essential to neurite
formation directed by insulin and insulin-like growth factors
AU **Ishii, Douglas N.**; Wang, Chiang; Li, Yi
CS Physiol. Dep., Colorado State Univ., Fort Collins, CO, 80523, USA
SO Adv. Exp. Med. Biol. (1991), 293(Mol. Biol. Physiol. Insulin
Insulin-Like Growth Factors), 361-78
CODEN: AEMBAP; ISSN: 0065-2598
DT Journal; General Review
LA English

L8 ANSWER 18 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1990:16837 CAPLUS
DN 112:16837
TI Stabilization of tubulin mRNAs by insulin and insulin-like growth
factor I during neurite formation
AU Fernyhough, P.; Mill, J. F.; Roberts, J. L.; **Ishii, D. N.**
CS Dep. Physiol., Colorado State Univ., Fort Collins, CO, 80523, USA
SO Mol. Brain Res. (1989), 6(2-3), 109-20
CODEN: MBREE4; ISSN: 0169-328X
DT Journal
LA English

L8 ANSWER 19 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1989:206568 CAPLUS
DN 110:206568
TI Relationship of insulin-like growth factor II gene expression in
muscle to synaptogenesis
AU **Ishii, Douglas N.**
CS Dep. Physiol., Colorado State Univ., Fort Collins, CO, 80523, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1989), 86(8), 2898-702
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English

L8 ANSWER 20 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1988:448522 CAPLUS
DN 109:48522
TI Insulin and related growth factors: effects on the nervous system
and mechanism for neurite growth and regeneration
AU Recio-Pinto, E.; **Ishii, D. N.**
CS Med. Cent., Cornell Univ., New York, NY, 10021, USA
SO Neurochem. Int. (1988), 12(4), 397-414
CODEN: NEUIDS; ISSN: 0197-0186
DT Journal; General Review
LA English

L8 ANSWER 21 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1988:198730 CAPLUS
DN 108:198730
TI Insulin and insulinlike growth factor receptors regulating neurite
formation in cultured human neuroblastoma cells
AU Recio-Pinto, E.; **Ishii, Douglas N.**
CS Med. Coll., Cornell Univ., New York, NY, USA
SO J. Neurosci. Res. (1988), 19(3), 312-20
CODEN: JNREDK; ISSN: 0360-4012
DT Journal
LA English

L8 ANSWER 22 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1987:150522 CAPLUS
DN 106:150522
TI Rat insulin-like growth factor II gene. A single gene with two
promoters expressing a multitranscript family
AU Soares, Marcelo Bento; Turken, Arthur; **Ishii, Douglas;**
Mills, Leslie; Episkopou, Vasso; Cotter, Sean; Zeitlin, Scott;
Efstratiadis, Argiris
CS Dep. Genet. Dev., Columbia Univ., New York, NY, 10032, USA
SO J. Mol. Biol. (1986), 192(4), 737-52
CODEN: JMOBAK; ISSN: 0022-2836
DT Journal
LA English

L8 ANSWER 23 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1986:455253 CAPLUS
DN 105:55253
TI Effects of insulin, insulin-like growth factor-II, and nerve growth
factor on neurite formation and survival in cultured sympathetic and
sensory neurons
AU Recio-Pinto, Esperanza; Rechler, Matthew M.; **Ishii, Douglas N.**
CS Lab. Biochem. Pharmacol., Natl. Inst. Arthritis, Metabol., Dig.
Dis., Bethesda, MD, 20205, USA
SO J. Neurosci. (1986), 6(5), 1211-9
CODEN: JNRSDS; ISSN: 0270-6474
DT Journal
LA English

L8 ANSWER 24 OF 43 CAPLUS COPYRIGHT 1998 ACS
AN 1984:433669 CAPLUS
DN 101:33669
TI Effects of insulin, insulin-like growth factor-II and nerve growth
factor on neurite outgrowth in cultured human neuroblastoma cells
AU Recio-Pinto, Esperanza; **Ishii, Douglas N.**
CS Coll. Phys. Surg., Columbia Univ., New York, NY, 10032, USA
SO Brain Res. (1984), 302(2), 323-34
CODEN: BRREAP; ISSN: 0006-8993
DT Journal
LA English

L8 ANSWER 25 OF 43 MEDLINE
AN 97476094 MEDLINE
DN 97476094
TI Insulin-like growth factor (**IGF**) gene expression is
reduced in neural tissues and liver from rats with
non-insulin-dependent diabetes mellitus, and **IGF** treatment
ameliorates diabetic neuropathy.
AU Zhuang H X; Wuarin L; Fei Z J; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins
80523, USA.
NC RO1-DK539222 (NIDDK)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1997 Oct)
283 (1) 366-74.
Journal code: JP3. ISSN: 0022-3565.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199801
EW 19980104

L8 ANSWER 26 OF 43 MEDLINE
AN 96363028 MEDLINE
DN 96363028
TI Differential spatio-temporal expression of the insulin-like growth
factor genes in regenerating sciatic nerve.
AU Pu S F; Zhuang H X; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins
80523, USA.
NC PO1 NS28323 (NINDS)
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1995 Dec 1) 34 (1) 18-28.
Journal code: MBR. ISSN: 0169-328X.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199703
EW 19970303

L8 ANSWER 27 OF 43 MEDLINE
AN 96340157 MEDLINE
DN 96340157
TI Brain insulin-like growth factor-II mRNA content is reduced in
insulin-dependent and non-insulin-dependent diabetes mellitus.
AU Wuarin L; Namdev R; Burns J G; Fei Z J; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins
805231, USA.
NC RO1 NS24327 (NINDS)
SO JOURNAL OF NEUROCHEMISTRY, (1996 Aug) 67 (2) 742-51.
Journal code: JAV. ISSN: 0022-3042.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199611

L8 ANSWER 28 OF 43 MEDLINE
AN 96309674 MEDLINE
DN 96309674
TI Insulin-like growth factors reverse or arrest diabetic neuropathy:

effects on hyperalgesia and impaired nerve regeneration in rats.
AU Zhuang H X; Snyder C K; Pu S F; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins 80523, USA.
NC R01 NS 24327 (NINDS)
SO EXPERIMENTAL NEUROLOGY, (1996 Aug) 140 (2) 198-205.
Journal code: EQF. ISSN: 0014-4886.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199610

L8 ANSWER 29 OF 43 MEDLINE
AN 96074488 MEDLINE
DN 96074488
TI Insulinlike growth factor gene expression in rat muscle during reinnervation.
AU Glazner G W; **Ishii D N**
CS Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins 80523, USA..
NC P01 NS28323 (NINDS)
SO MUSCLE AND NERVE, (1995 Dec) 18 (12) 1433-42.
Journal code: NN9. ISSN: 0148-639X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199602

L8 ANSWER 30 OF 43 MEDLINE
AN 95230709 MEDLINE
DN 95230709
TI Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats.
AU **Ishii D N**; Lupien S B
CS Department of Physiology, Colorado State University, Fort Collins 80523..
NC R01 NS23427 (NINDS)
SO JOURNAL OF NEUROSCIENCE RESEARCH, (1995 Jan 1) 40 (1) 138-44.
Journal code: KAC. ISSN: 0360-4012.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199507

L8 ANSWER 31 OF 43 MEDLINE
AN 95227210 MEDLINE
DN 95227210
TI Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy.
AU **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins 80523, USA..
NC RO1NS24327 (NINDS)
SO BRAIN RESEARCH. BRAIN RESEARCH REVIEWS, (1995 Jan) 20 (1) 47-67.
Ref: 239
Journal code: BRS. ISSN: 0165-0173.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 199507

L8 ANSWER 32 OF 43 MEDLINE
AN 95172323 MEDLINE
DN 95172323
TI Reduced insulin-like growth factor-I mRNA content in liver, adrenal glands and spinal cord of diabetic rats.
AU **Ishii D N**; Guertin D M; Whalen L R
CS Department of Physiology, Colorado State University, Fort Collins 80523..
NC RO1 NS24327 (NINDS)
SO DIABETOLOGIA, (1994 Nov) 37 (11) 1073-81.
Journal code: E93. ISSN: 0012-186X.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199506

L8 ANSWER 33 OF 43 MEDLINE
AN 95121409 MEDLINE
DN 95121409
TI Early reduction in insulin-like growth factor gene expression in diabetic nerve.
AU Wuarin L; Guertin D M; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins 80523..
NC RO1 NS24327 (NINDS)
SO EXPERIMENTAL NEUROLOGY, (1994 Nov) 130 (1) 106-14.
Journal code: EQF. ISSN: 0014-4886.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199504

L8 ANSWER 34 OF 43 MEDLINE
AN 95107044 MEDLINE
DN 95107044
TI Elevated insulin-like growth factor (**IGF**) gene expression in sciatic nerves during **IGF**-supported nerve regeneration.
AU Glazner G W; Morrison A E; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins 80523.
NC P01 NS28323 (NINDS)
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1994 Sep) 25 (3-4) 265-72.
Journal code: MBR. ISSN: 0169-328X.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199504

L8 ANSWER 35 OF 43 MEDLINE
AN 95083707 MEDLINE
DN 95083707
TI Role of insulin-like growth factors in peripheral nerve

regeneration.
AU **Ishii D N**; Glazner G W; Pu S F
CS Department of Physiology, Colorado State University, Fort Collins
80523..
NC 1P01 NS28323 (NINDS)
SO PHARMACOLOGY AND THERAPEUTICS, (1994 Apr-May) 62 (1-2) 125-44. Ref: 135
Journal code: P44. ISSN: 0163-7258.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199503

L8 ANSWER 36 OF 43 MEDLINE
AN 93101597 MEDLINE
DN 93101597
TI Insulin-like growth factor II stimulates motor nerve regeneration.
AU Near S L; Whalen L R; Miller J A; **Ishii D N**
CS Department of Anatomy and Neurobiology, Colorado State University,
Fort Collins 80523..
NC R01 NS24787 (NINDS)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES
OF AMERICA, (1992 Dec 15) 89 (24) 11716-20.
Journal code: PV3. ISSN: 0027-8424.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199303

L8 ANSWER 37 OF 43 MEDLINE
AN 92326572 MEDLINE
DN 92326572
TI Effects of insulin and insulin-like growth factors on neurofilament
mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells.
AU Wang C; Li Y; Wible B; Angelides K J; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins
80523.
NC P01 NS28323 (NINDS)
R01 NS24787 (NINDS)
NS26733 (NINDS)
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1992 May) 13 (4) 289-300.
Journal code: MBR. ISSN: 0169-328X.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199210

L8 ANSWER 38 OF 43 MEDLINE
AN 90135914 MEDLINE
DN 90135914
TI Stabilization of tubulin mRNAs by insulin and insulin-like growth
factor I during neurite formation.
AU Fernyhough P; Mill J F; Roberts J L; **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins
80523.
NC R01 NS 24327 (NINDS)
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1989 Nov) 6 (2-3) 109-20.
Journal code: MBR. ISSN: 0169-328X.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199005

L8 ANSWER 39 OF 43 MEDLINE
AN 89202433 MEDLINE
DN 89202433
TI Relationship of insulin-like growth factor II gene expression in
muscle to synaptogenesis.
AU **Ishii D N**
CS Department of Physiology, Colorado State University, Fort Collins
80523.
NC R01 NS24787 (NINDS)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES
OF AMERICA, (1989 Apr) 86 (8) 2898-902.
Journal code: PV3. ISSN: 0027-8424.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 198907

L8 ANSWER 40 OF 43 MEDLINE
AN 88245201 MEDLINE
DN 88245201
TI Insulin and insulinlike growth factor receptors regulating neurite
formation in cultured human neuroblastoma cells.
AU Recio-Pinto E; **Ishii D N**
CS Department of Anesthesiology, Medical College, Cornell University,
New York, New York.
NC R01 NS24787 (NINDS)
SO JOURNAL OF NEUROSCIENCE RESEARCH, (1988 Mar) 19 (3) 312-20.
Journal code: KAC. ISSN: 0360-4012.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198809

L8 ANSWER 41 OF 43 MEDLINE
AN 87226166 MEDLINE
DN 87226166
TI Rat insulin-like growth factor II gene. A single gene with two
promoters expressing a multitranscript family.
AU Soares M B; Turken A; **Ishii D**; Mills L; Episkopou V;
Cotter S; Zeitlin S; Efstratiadis A
SO JOURNAL OF MOLECULAR BIOLOGY, (1986 Dec 20) 192 (4) 737-52.
Journal code: J6V. ISSN: 0022-2836.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 198709

L8 ANSWER 42 OF 43 MEDLINE
AN 86226464 MEDLINE

DN 86226464
TI Effects of insulin, insulin-like growth factor-II, and nerve growth
factor on neurite formation and survival in cultured sympathetic and
sensory neurons.
AU Recio-Pinto E; Rechler M M; **Ishii D N**
NC R01 AM32841 (NIADDK)
SO JOURNAL OF NEUROSCIENCE, (1986 May) 6 (5) 1211-9.
Journal code: JDF. ISSN: 0270-6474.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198609

L8 ANSWER 43 OF 43 MEDLINE
AN 84233406 MEDLINE
DN 84233406
TI Effects of insulin, insulin-like growth factor-II and nerve growth
factor on neurite outgrowth in cultured human neuroblastoma cells.
AU Recio-Pinto E; **Ishii D N**
NC R01 NS 14218 (NINDS)
R01 AM32841 (NIADDK)
1K04 NS 00375 (NINDS)
+
SO BRAIN RESEARCH, (1984 Jun 8) 302 (2) 323-34.
Journal code: B5L. ISSN: 0006-8993.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198410

=> file uspatfull

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
49.22 170.82

FILE 'USPATFULL' ENTERED AT 20:34:45 ON 26 APR 1998
CA INDEXING COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE:
21 Apr 1998 (19980421/PD)
FILE LAST UPDATED: 22 Apr 1998 (19980422/ED)
HIGHEST PATENT NUMBER: US5742935
CA INDEXING IS CURRENT THROUGH 22 Apr 1998 (19980422/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH:
21 Apr 1998 (19980421/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:
JAN 1998
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 1998

>>> Page images are available for patents from 1/1/95. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<
>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> e ishii, d/in

E1	2		ISHII YUUKO/IN
E2	4		ISHII YUWA/IN
E3	0	-->	ISHII, D/IN
E4	1		ISHIIDE HIDENORI/IN
E5	7		ISHIIZUMI SEIICHI/IN
E6	1		ISHIJIMA AKIRA/IN
E7	2		ISHIJIMA CHIEKO/IN
E8	8		ISHIJIMA HIROSHI/IN
E9	1		ISHIJIMA HIROYASU/IN
E10	2		ISHIJIMA HISASHI/IN
E11	1		ISHIJIMA ICHIRO/IN
E12	1		ISHIJIMA KEIZO/IN

=> e ishii d/au

E1	2		ISHII CHIHO/AU
E2	1		ISHII CHISEKI/AU
E3	0	-->	ISHII D/AU
E4	2		ISHII DAIDO/AU
E5	2		ISHII DAIROKU/AU
E6	12		ISHII DAISUKE/AU
E7	1		ISHII DECEASED HISAO/AU
E8	1		ISHII DECEASED RYOICHI/AU
E9	13		ISHII EIICHI/AU
E10	3		ISHII EIJI/AU
E11	1		ISHII ETUMI/AU
E12	13		ISHII FUMIAKI/AU